All conditions

Ovarian Cancer

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

322
Trials tracked
6
Recruiting now
37
Australian sites
64
Countries
Country

Showing 322 trials

🇦🇺 AU site

Trial: NCT05277051 — GlaxoSmithKline

NCT05277051 · GlaxoSmithKline
Active, Not Recruiting Phase 1 Est. completion 31 August 2027
🇦🇺 AU 🇨🇦 CA 🇨🇳 CN 🇫🇷 FR 🇯🇵 JP

**Who might be able to join this trial:** - Women who are not pregnant or breastfeeding, and who are either unable to become pregnant or are using a highly effective form of birth control (with a failure rate of less than 1% per year) duri...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT04205227 — ENB Therapeutics, Inc

NCT04205227 · ENB Therapeutics, Inc
Active, Not Recruiting Phase 2 Est. completion 1 January 2026
🇦🇺 AU 🇺🇸 US

**Who might be able to join this trial:** *For all participants:* - You must be at least 18 years old and willing to sign a consent form. - You must have a life expectancy of more than 3 months. - You must have tumor tissue samples (either...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT06003231 — Seagen, a wholly owned subsidiary of Pfizer

NCT06003231 · Seagen, a wholly owned subsidiary of Pfizer
Active, Not Recruiting Phase 2 Est. completion 27 March 2026
🇦🇺 AU 🇨🇦 CA 🇮🇹 IT 🇰🇷 KR 🇪🇸 ES

**Who might be able to join this trial:** - You have been diagnosed with one of the following cancers (confirmed by a lab/biopsy): head and neck cancer (from the mouth, salivary glands, voice box, or throat — but NOT the nasopharynx), non-...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT06533059 — Alterome Therapeutics, Inc.

NCT06533059 · Alterome Therapeutics, Inc.
Active, Not Recruiting Phase 1 Est. completion 29 December 2026
🇦🇺 AU 🇫🇷 FR 🇯🇵 JP 🇰🇷 KR 🇪🇸 ES

Who might be able to join this trial: - You have been diagnosed with a solid tumor cancer that has a specific genetic change called "AKT1 E17K mutation," confirmed through laboratory genetic testing. - Your cancer cannot be removed with sur...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00483782 — Medical Research Council

NCT00483782 · Medical Research Council
Completed Phase 3
🇦🇺 AU 🇫🇷 FR 🇩🇪 DE 🇳🇴 NO 🇬🇧 GB

**Who might be able to join this trial:** - You have been diagnosed for the first time with cancer of the ovaries, fallopian tubes, or the lining of the abdominal cavity (peritoneum), confirmed by a tissue sample examination - Your cancer...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT03414047 — Eli Lilly and Company

NCT03414047 · Eli Lilly and Company
Completed Phase 2 Est. completion 3 June 2019
🇦🇺 AU 🇧🇪 BE 🇮🇱 IL 🇮🇹 IT 🇰🇷 KR

**Who might be able to join this trial:** - You are a woman diagnosed with a specific type of ovarian, peritoneal, or fallopian tube cancer called "high-grade serous." - (Cohorts 1–3) Your cancer has stopped responding to platinum-based ch...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00086892 — Gynecologic Oncology Group

NCT00086892 · Gynecologic Oncology Group
Completed Phase 2 Est. completion 1 April 2006
🇦🇺 AU 🇨🇦 CA 🇯🇵 JP 🇳🇴 NO 🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with ovarian cancer or primary peritoneal cancer (confirmed by a lab test on tissue samples) that has come back after previous treatment - Your cancer can be measured on a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT01253681 — Amgen

NCT01253681 · Amgen
Completed Phase 1 Est. completion 1 October 2012
🇦🇺 AU 🇧🇪 BE 🇪🇸 ES

Who might be able to join this trial: - You are a woman aged 18 or older who has been newly diagnosed with a specific type of ovarian, peritoneal, or fallopian tube cancer (certain aggressive or advanced stages) and are planned to receive 6...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00003597 — Children's Oncology Group

NCT00003597 · Children's Oncology Group
Completed Phase 1 Est. completion 1 October 2004
🇦🇺 AU 🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a solid tumour (such as a sarcoma, kidney tumour, brain tumour, germ cell tumour, melanoma, retinoblastoma, or liver tumour) that has been confirmed by a tissue sampl...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00053352 — Children's Oncology Group

NCT00053352 · Children's Oncology Group
Completed Phase 3 Est. completion 1 October 2013
🇦🇺 AU 🇨🇦 CA 🇳🇿 NZ Puerto Rico 🇨🇭 CH

**Who might be able to join this trial:** - You have a germ cell tumor located outside the brain that contains at least one of these tumor types: yolk sac tumor, embryonal carcinoma, or choriocarcinoma (mixed tumors that also contain matur...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT03150810 — BeiGene

NCT03150810 · BeiGene
Completed Phase 1 Est. completion 4 May 2023
🇦🇺 AU 🇪🇸 ES 🇬🇧 GB 🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older and have an advanced or spreading (metastatic) solid tumour cancer - You are relatively active and able to carry out daily activities with little or no limitation...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT04296890 — ImmunoGen, Inc.

NCT04296890 · ImmunoGen, Inc.
Completed Phase 3 Est. completion 16 November 2021
🇦🇺 AU 🇧🇪 BE 🇧🇬 BG 🇨🇿 CZ 🇩🇪 DE

**Who might be able to join this trial:** - You are a woman aged 18 or older - You have been diagnosed with high-grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer - Your cancer has been confirmed to be "plati...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT04430842 — Quadriga Biosciences, Inc.

NCT04430842 · Quadriga Biosciences, Inc.
Completed Phase 1 Est. completion 21 September 2022
🇦🇺 AU

**Who might be able to join this trial:** - You are 18 years old or older - Your bone marrow, kidneys, and liver are functioning well enough (as determined by blood tests) - Any side effects from previous cancer treatments have mostly clea...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT01204749 — Amgen

NCT01204749 · Amgen
Completed Phase 3 Est. completion 1 March 2013
🇦🇺 AU 🇧🇪 BE 🇧🇷 BR 🇧🇬 BG 🇨🇦 CA

**Who might be able to join this trial:** - You are a woman aged 18 or older at the time you sign the consent form - You are in good enough general health to carry out light activity and care for yourself (your doctor will assess this) - Y...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00020696 — Gynecologic Oncology Group

NCT00020696 · Gynecologic Oncology Group
Completed Phase 2 Est. completion 1 April 2006
🇦🇺 AU 🇨🇦 CA 🇬🇧 GB 🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with ovarian cancer or primary peritoneal cancer that has been confirmed by a tissue sample (biopsy), and it has either persisted or come back after treatment - Your cancer...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT01078662 — AstraZeneca

NCT01078662 · AstraZeneca
Completed Phase 2 Est. completion 31 July 2012
🇦🇺 AU 🇩🇪 DE 🇮🇱 IL 🇪🇸 ES 🇸🇪 SE

**Who might be able to join this trial:** - You have been tested and confirmed to carry a harmful (or possibly harmful) change in the BRCA1 or BRCA2 gene (a gene mutation linked to cancer risk), confirmed before joining the study - You have...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT03126110 — Incyte Biosciences International Sàrl

NCT03126110 · Incyte Biosciences International Sàrl
Completed Phase 2 Est. completion 9 November 2021
🇦🇺 AU 🇧🇪 BE 🇪🇸 ES 🇺🇸 US

**Who might be able to join this trial:** - Your cancer has spread to nearby areas or other parts of the body, and surgery to fully remove it is not possible. - (Phase 1 only) You have any type of advanced or metastatic solid tumor cancer....

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00098878 — NHS Greater Glasgow and Clyde

NCT00098878 · NHS Greater Glasgow and Clyde
Completed Phase 3 Est. completion 1 July 2010
🇦🇺 AU 🇳🇿 NZ 🇬🇧 GB

**Who might be able to join this trial:** - You have been diagnosed with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, confirmed by a tissue sample (biopsy) or cell test (cytology) - Your cancer is at Stage IC, II, I...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT01113957 — AbbVie (prior sponsor, Abbott)

NCT01113957 · AbbVie (prior sponsor, Abbott)
Completed Phase 2 Est. completion 1 June 2013
🇦🇺 AU 🇨🇦 CA 🇭🇺 HU 🇮🇱 IL 🇳🇿 NZ

**Who might be able to join this trial:** - You have been diagnosed with recurrent high-grade serous ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, confirmed by a tissue or cell sample. - You have had at least 1 chemo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00604994 — Queensland Centre for Gynaecological Cancer

NCT00604994 · Queensland Centre for Gynaecological Cancer
Completed Not Applicable Est. completion 1 January 2013
🇦🇺 AU

Who might be able to join this trial: - You are scheduled to have surgery for a gynaecological condition (either non-cancerous or cancerous), agreed upon by you and your surgeon. - You are female and not pregnant. - You are 18 years of age...

🇦🇺 AU site

Trial: NCT04460768 — AstraZeneca

NCT04460768 · AstraZeneca
Completed Not Applicable Est. completion 10 November 2020
🇦🇺 AU 🇰🇷 KR 🇹🇼 TW

**Who might be able to join this trial:** - You are a woman aged 18 or older - You have been diagnosed with advanced ovarian cancer (known as stage III or IV) of a specific type called epithelial ovarian cancer (this includes several subtyp...

🇦🇺 AU site

Trial: NCT00262990 — Novartis Pharmaceuticals

NCT00262990 · Novartis Pharmaceuticals
Completed Phase 3 Est. completion 1 February 2010
🇦🇺 AU 🇨🇦 CA 🇩🇰 DK 🇫🇮 FI 🇫🇷 FR

Who might be able to join this trial: - You are 18 years of age or older - You have been diagnosed with ovarian, fallopian tube, or peritoneal cancer - You have received no more than three rounds (regimens) of chemotherapy treatment - Your...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT07059845 — AbbVie

NCT07059845 · AbbVie
Recruiting Phase 2 Est. completion 1 January 2029
🇦🇺 AU 🇧🇪 BE 🇨🇿 CZ 🇩🇰 DK 🇫🇷 FR

Who might be able to join this trial: **All parts of the trial require:** - You must be willing to provide a stored tumor tissue sample or agree to a new tumor biopsy (using a low-risk, routine procedure) so that the tumor can be tested fo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT04294927 — University Medical Center Nijmegen

NCT04294927 · University Medical Center Nijmegen
Recruiting Not Applicable Est. completion 17 February 2040
🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR 🇨🇦 CA

Who might be able to join this trial: - You are a woman who has been confirmed to carry a specific harmful gene mutation in one of these genes: BRCA1, BRCA2, RAD51C, RAD51D, or BRIP1, tested at one of the participating medical centres - You...

🇦🇺 AU site

Trial: NCT04585750 — PMV Pharmaceuticals, Inc

NCT04585750 · PMV Pharmaceuticals, Inc
Recruiting Phase 2 Est. completion 15 August 2026
🇦🇺 AU 🇫🇷 FR 🇩🇪 DE 🇮🇹 IT 🇸🇬 SG

**Who might be able to join this trial:** - You are at least 18 years old, or between 12 and 17 years old if a special safety committee has given approval. - You have an advanced or spreading solid tumor cancer that has a specific gene cha...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT06400472 — Eli Lilly and Company

NCT06400472 · Eli Lilly and Company
Recruiting Phase 1 Est. completion 1 February 2027
🇦🇺 AU 🇫🇷 FR 🇮🇹 IT 🇯🇵 JP 🇰🇷 KR

Who might be able to join this trial: - You have been diagnosed with one of the following cancers (depending on which part of the trial you join): ovarian cancer (including primary peritoneal or fallopian tube cancer), endometrial cancer, c...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT06819007 — Daiichi Sankyo

NCT06819007 · Daiichi Sankyo
Recruiting Phase 3 Est. completion 1 November 2028
🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR 🇧🇬 BG

**Who might be able to join this trial:** - You must be willing to sign consent forms before any trial-related procedures begin, including consent for optional genetic testing. - You must be 18 years of age or older at the time of signing...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT06751329 — Xadcera Biopharmaceutical (Suzhou) Co., Ltd.

NCT06751329 · Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
Recruiting Phase 1 Est. completion 8 October 2027
🇦🇺 AU 🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older at the time of signing the consent form. - You are able to understand and willing to sign a written consent form agreeing to take part. - You are reasonably activ...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT03746431 — Fusion Pharmaceuticals Inc.

NCT03746431 · Fusion Pharmaceuticals Inc.
Terminated Phase 1 Est. completion 3 December 2025
🇦🇺 AU 🇨🇦 CA 🇺🇸 US

**Who might be able to join this trial:** - You have been confirmed by a lab test to have an advanced solid tumour cancer that has not responded to standard treatments, has no standard treatments available, or you have chosen not to have s...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT05317078 — Amgen

NCT05317078 · Amgen
Terminated Phase 1 Est. completion 19 December 2023
🇦🇺 AU 🇨🇭 CH 🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older. - You have a solid tumor cancer that has been confirmed by a lab test, and your tumor produces a protein called claudin-6 (CLDN6) — this may include lung cancer,...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT05329545 — Mersana Therapeutics

NCT05329545 · Mersana Therapeutics
Terminated Phase 3 Est. completion 29 September 2023
🇦🇺 AU 🇨🇦 CA 🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a specific type of ovarian cancer called high-grade serous ovarian cancer (including cancer that started in the fallopian tubes or the lining of the abdomen), and it...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00849667 — Morphotek

NCT00849667 · Morphotek
Terminated Phase 3 Est. completion 31 December 2012
🇦🇷 AR 🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR

**Who might be able to join this trial:** - You have been diagnosed with a specific type of ovarian cancer (non-mucinous epithelial ovarian cancer), or a related cancer starting in the peritoneum or fallopian tubes, confirmed by a lab test...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT04851834 — Xennials Therapeutics Australia Pty Ltd

NCT04851834 · Xennials Therapeutics Australia Pty Ltd
Terminated Phase 2 Est. completion 8 November 2022
🇦🇺 AU

**Who might be able to join this trial:** - You are 18 years of age or older - You are willing and able to give your consent to participate in the trial - You have been diagnosed with an advanced or spreading solid tumour cancer (confirmed...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT05756907 — Sonnet BioTherapeutics

NCT05756907 · Sonnet BioTherapeutics
Terminated Phase 2 Est. completion 31 December 2025
🇦🇺 AU 🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older at the time of signing the consent form. - For the first part of the trial: You have a solid tumor cancer that has spread or cannot be removed with surgery, you h...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT03691012 — Walter and Eliza Hall Institute of Medical Research

NCT03691012 · Walter and Eliza Hall Institute of Medical Researc...
UNKNOWN Not Applicable Est. completion 31 December 2020
🇦🇺 AU 🇺🇸 US

**Who might be able to join this trial:** - You have had surgery to remove ovarian, fallopian tube, or peritoneal cancer (specific types: high grade serous, endometrioid, clear cell carcinoma, or carcinosarcoma) at stage I through IV, and...

🇦🇺 AU site

Trial: NCT03210298 — Sabine Rhode

NCT03210298 · Sabine Rhode
UNKNOWN Not Applicable Est. completion 1 September 2022
🇦🇷 AR 🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇩🇰 DK

Who might be able to join this trial: - You have been diagnosed with colorectal cancer (cancer of the colon or rectum) - You have been diagnosed with ovarian cancer - You have been diagnosed with gastric cancer (stomach cancer) - You have b...

🇦🇺 AU site

Trial: NCT01624493 — Hoosier Cancer Research Network

NCT01624493 · Hoosier Cancer Research Network
Withdrawn Phase 2 Est. completion 1 July 2014
🇦🇺 AU 🇳🇿 NZ 🇺🇸 US

**Who might be able to join this trial:** **For the early phase (Phase I) of the trial:** - You have been diagnosed with ovarian cancer, primary peritoneal cancer, or fallopian tube cancer that has been confirmed by a lab test, including a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT04498117 — CanariaBio Inc.

NCT04498117 · CanariaBio Inc.
Active, Not Recruiting Phase 3 Est. completion 26 December 2026
🇦🇷 AR 🇧🇪 BE 🇧🇷 BR 🇨🇦 CA 🇨🇱 CL

**Who might be able to join this trial:** - You are 18 years old or older. - You have been newly diagnosed with a specific type of ovarian, fallopian tube, or peritoneal cancer (called epithelial adenocarcinoma) that is at an advanced stag...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02194387 — M.D. Anderson Cancer Center

NCT02194387 · M.D. Anderson Cancer Center
Active, Not Recruiting Not Applicable Est. completion 30 September 2027
🇺🇸 US

**Who might be able to join this trial:** - Your Body Mass Index (BMI) is 25 or higher, OR you do less than 150 minutes of moderate to vigorous exercise per week, OR you eat fewer than 5 servings of fruit and vegetables per day - You are p...

Trial: NCT03836352 — ImmunoVaccine Technologies, Inc. (IMV Inc.)

NCT03836352 · ImmunoVaccine Technologies, Inc. (IMV Inc.)
Active, Not Recruiting Phase 2 Est. completion 31 December 2023
🇨🇦 CA 🇺🇸 US

**Who might be able to join this trial:** - You have an advanced or spreading form of one of these cancers: ovarian, fallopian tube, or peritoneal cancer; liver cancer (hepatocellular carcinoma); non-small cell lung cancer; bladder/urinary...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02521844 — EDDC (Experimental Drug Development Centre), A*STAR Research Entities

NCT02521844 · EDDC (Experimental Drug Development Centre), A*STA...
Active, Not Recruiting Phase 1 Est. completion 31 October 2024
🇸🇬 SG 🇺🇸 US

**Who might be able to join this trial:** - You are at least 18 years old (in the US) or at least 21 years old (in Singapore) - You are able to understand and sign a consent form agreeing to take part in the study - You have been diagnosed...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01421095 — University of California, San Diego

NCT01421095 · University of California, San Diego
Active, Not Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You must have had your first menstrual period at some point (even if periods have stopped since) - You have been diagnosed with cancer - You have previously received treatment that may have affect...

Trial: NCT03602859 — Tesaro, Inc.

NCT03602859 · Tesaro, Inc.
Active, Not Recruiting Phase 3 Est. completion 31 October 2024
Belarus 🇧🇪 BE 🇨🇦 CA 🇨🇿 CZ 🇩🇰 DK

**Who might be able to join this trial:** - You must be a woman aged 18 or older who can understand the study and agrees to take part by signing a consent form. - You must have a confirmed diagnosis of a specific type of high-grade ovarian...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT07392476 — The Cleveland Clinic

NCT07392476 · The Cleveland Clinic
Active, Not Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 45 years old - You have been diagnosed with Polycystic Ovary Syndrome (PCOS) by a doctor using standard diagnostic methods - Your Body Mass Index (BMI) is greater than 25 kg...

Trial: NCT02644369 — University Health Network, Toronto

NCT02644369 · University Health Network, Toronto
Active, Not Recruiting Phase 2 Est. completion 1 December 2026
🇨🇦 CA

Who might be able to join this trial: - You must be willing and able to sign a consent form agreeing to take part in the trial. - You must be 18 years old or older at the time of signing the consent form. - You must have a solid tumour canc...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT06714617 — SystImmune Inc.

NCT06714617 · SystImmune Inc.
Active, Not Recruiting Phase 1 Est. completion 1 September 2027
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older - You weigh more than 40 kg (about 88 lbs); if the dose being tested is below a certain level, you must weigh at least 70 kg (about 154 lbs) - You have a life expect...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05652283 — Bai-Rong Xia

NCT05652283 · Bai-Rong Xia
Active, Not Recruiting Phase 2 Est. completion 31 May 2024
🇨🇳 CN

**Who might be able to join this trial:** - You must be willing to sign a consent form before any part of the trial begins. - You must be a woman aged 18 or older. - You must have been diagnosed through a tissue sample (taken by surgery or...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT06972693 — European Institute of Oncology

NCT06972693 · European Institute of Oncology
Active, Not Recruiting Phase 4 Est. completion 30 December 2025
🇮🇹 IT

**Who might be able to join this trial:** - You are 18 years of age or older - You have agreed to take part and signed a consent form - You have been diagnosed with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, confir...

Phase 4: Approved of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03883542 — Universitair Ziekenhuis Brussel

NCT03883542 · Universitair Ziekenhuis Brussel
Active, Not Recruiting Not Applicable Est. completion 31 December 2026
🇧🇪 BE

Who might be able to join this trial: - Preserved tumour tissue samples (stored in paraffin wax) from the original borderline ovarian tumour must be available and in good enough condition for DNA testing. - The original tissue slides from t...

Trial: NCT05056077 — University of California, San Francisco

NCT05056077 · University of California, San Francisco
Active, Not Recruiting Not Applicable Est. completion 30 April 2027
🇺🇸 US

**Who might be able to join this trial:** **For cancer survivors:** - You are 18 years of age or older. - You have been diagnosed with bladder, breast, colon, endometrial, kidney (renal cell carcinoma), ovarian, prostate, or rectal cancer....

Trial: NCT04569773 — Memorial Sloan Kettering Cancer Center

NCT04569773 · Memorial Sloan Kettering Cancer Center
Active, Not Recruiting Not Applicable Est. completion 23 September 2026
🇺🇸 US

**Who might be able to join this trial:** - You are a woman between 18 and 50 years old - You have not yet gone through menopause - Your uterine cancer has been identified as a specific type called "endometrioid" based on tissue testing - Y...

Trial: NCT03939481 — SWOG Cancer Research Network

NCT03939481 · SWOG Cancer Research Network
Active, Not Recruiting Not Applicable Est. completion 8 April 2025
🇨🇱 CL 🇨🇴 CO 🇲🇽 MX 🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with stage I, II, or III lung cancer (non-small cell type), breast cancer, or ovarian cancer — stage IV does not qualify. - You are planning to start chemotherapy using a...

Trial: NCT02828618 — AGO Study Group

NCT02828618 · AGO Study Group
Active, Not Recruiting Not Applicable Est. completion 1 February 2025
🇦🇹 AT 🇩🇰 DK 🇫🇷 FR 🇩🇪 DE 🇮🇹 IT

**Who might be able to join this trial:** - You have been newly diagnosed with a type of ovarian cancer (invasive epithelial ovarian cancer) that has spread to an advanced stage (stage IIIB–IV), and if stage IV, the spread must be in a loc...

Trial: NCT04862325 — Hospital Clinic of Barcelona

NCT04862325 · Hospital Clinic of Barcelona
Active, Not Recruiting Not Applicable Est. completion 20 February 2026
🇪🇸 ES

**Who might be able to join this trial:** - You have advanced ovarian cancer and are scheduled for surgery (either as a first operation, after 3–4 rounds of chemotherapy, or as a second or third surgery). - You are able to carry out at leas...

Trial: NCT02873962 — Dana-Farber Cancer Institute

NCT02873962 · Dana-Farber Cancer Institute
Active, Not Recruiting Phase 2 Est. completion 1 February 2025
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with ovarian cancer, fallopian tube cancer, or peritoneal cancer, confirmed by a tissue or cell sample — any cancer type or grade is accepted - You have already received a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05620134 — Salubris Biotherapeutics Inc

NCT05620134 · Salubris Biotherapeutics Inc
Active, Not Recruiting Phase 2 Est. completion 17 October 2025
🇧🇪 BE 🇪🇸 ES

**Who might be able to join this trial:** - You must be 18 years of age or older. - You must be willing to sign a consent form and be able to follow the study schedule and procedures. - For the dose-finding part of the trial, you must have...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05953883 — Fondazione Policlinico Universitario Agostino Gemelli IRCCS

NCT05953883 · Fondazione Policlinico Universitario Agostino Geme...
Active, Not Recruiting Not Applicable Est. completion 17 November 2023
🇮🇹 IT

**Who might be able to join this trial:** - You have been recently diagnosed with advanced ovarian cancer (a specific stage called FIGO stage IIIA or higher) and your treatment plan includes chemotherapy before surgery, followed by surgery...

Trial: NCT02298959 — National Cancer Institute (NCI)

NCT02298959 · National Cancer Institute (NCI)
Active, Not Recruiting Phase 1 Est. completion 21 May 2025
🇨🇦 CA 🇺🇸 US

**Who might be able to join this trial:** - You have cancer that has spread to other parts of your body, confirmed by a tissue or cell sample — the specific cancer types allowed depend on which part of the trial you are entering (any solid...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05415527 — Institut Bergonié

NCT05415527 · Institut Bergonié
Active, Not Recruiting Not Applicable Est. completion 10 June 2027
🇫🇷 FR

Who might be able to join this trial: - You must be 18 years old or older. - You must have a type of ovarian cancer that cannot be removed by surgery straight away and requires chemotherapy both before and after surgery. - You must be plann...

Trial: NCT05220033 — Rutgers, The State University of New Jersey

NCT05220033 · Rutgers, The State University of New Jersey
Active, Not Recruiting Not Applicable Est. completion 1 July 2026
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with ovarian cancer, peritoneal cancer, or fallopian tube cancer (any stage), or had a recurrence within the past 5 years - You have been diagnosed with endometrial cancer...

Trial: NCT07109414 — Novita Pharmaceuticals, Inc.

NCT07109414 · Novita Pharmaceuticals, Inc.
Active, Not Recruiting Phase 3 Est. completion 25 October 2028
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a specific type of ovarian cancer called high-grade serous carcinoma, confirmed by a lab test - Your cancer has stopped responding to platinum-based chemotherapy (kno...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01696968 — National Cancer Institute (NCI)

NCT01696968 · National Cancer Institute (NCI)
Active, Not Recruiting Not Applicable Est. completion 21 May 2012
🇺🇸 US

**Who might be able to join this trial:** - People who are aged 55 to 74 years old at the time they join the trial - People who are willing and able to sign a consent form agreeing to take part **Who may not be able to join:** - People who...

Trial: NCT05763199 — University of California, Davis

NCT05763199 · University of California, Davis
Active, Not Recruiting Phase 2 Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with ovarian, fallopian tube, or peritoneal cancer that was confirmed by a tissue or cell sample, including various types of this cancer - Your cancer was diagnosed at any...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT04065009 — Karolinska Institutet

NCT04065009 · Karolinska Institutet
Active, Not Recruiting Phase 3 Est. completion 10 January 2024
🇸🇪 SE

**Who might be able to join this trial:** - You have been assessed as generally healthy enough for surgery, with none, mild, or moderate pre-existing health conditions (confirm with trial site) - You are scheduled for upfront surgery to rem...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00565851 — National Cancer Institute (NCI)

NCT00565851 · National Cancer Institute (NCI)
Active, Not Recruiting Phase 3 Est. completion 30 April 2019
🇯🇵 JP 🇰🇷 KR 🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a recurrent (come-back) cancer of the ovaries, the lining of the abdomen (peritoneal), or the fallopian tubes, confirmed by a tissue sample. - Your cancer is one of t...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05875233 — Zenchi, Inc.

NCT05875233 · Zenchi, Inc.
Active, Not Recruiting Not Applicable Est. completion 30 August 2024
🇺🇸 US

Who might be able to join this trial: - You are a woman between 18 and 36 years old. - You have been diagnosed with polycystic ovary syndrome (PCOS) within the last 5 years. - You have experienced at least two of the following: irregular or...

Trial: NCT07546578 — Fondazione Policlinico Universitario Agostino Gemelli IRCCS

NCT07546578 · Fondazione Policlinico Universitario Agostino Geme...
Active, Not Recruiting Not Applicable Est. completion 15 August 2026
🇮🇹 IT

Who might be able to join this trial: - You have been diagnosed with epithelial ovarian cancer, but not the mucinous type of ovarian cancer - Blood plasma samples taken before your surgery and again 4 to 7 weeks after your surgery are avail...

Trial: NCT04742075 — Nordic Society of Gynaecological Oncology - Clinical Trials Unit

NCT04742075 · Nordic Society of Gynaecological Oncology - Clinic...
Active, Not Recruiting Phase 2 Est. completion 1 May 2026
🇩🇰 DK

**Who might be able to join this trial:** - You are able to understand and sign a consent form before joining the trial - You have been diagnosed (confirmed by tissue sample) with epithelial ovarian cancer, fallopian tube cancer, or primar...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00002540 — National Cancer Institute (NCI)

NCT00002540 · National Cancer Institute (NCI)
Active, Not Recruiting Not Applicable Est. completion 21 May 2012
🇺🇸 US

**Who might be able to join this trial:** - You are a man who is at least 55 years old but not yet 75 years old at the time of joining the trial - You are willing and able to read and sign a consent form agreeing to take part **Who may not...

Trial: NCT01608074 — Centre Oscar Lambret

NCT01608074 · Centre Oscar Lambret
Active, Not Recruiting Not Applicable Est. completion 1 August 2033
🇫🇷 FR

Who might be able to join this trial: - You are a woman aged 35 or older - You have finished having children and are not planning any more pregnancies - You carry a BRCA1 or BRCA2 gene mutation, or you have a family history of breast or ova...

Trial: NCT00696111 — University of Chicago

NCT00696111 · University of Chicago
Completed Not Applicable Est. completion 30 June 2022
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with Polycystic Ovary Syndrome (PCOS) - You are obese, meaning your Body Mass Index (BMI) is 30 or higher Who may not be able to join: - You have been diagnosed with certain h...

Trial: NCT01609556 — ImmunoGen, Inc.

NCT01609556 · ImmunoGen, Inc.
Completed Phase 1 Est. completion 19 March 2018
🇨🇦 CA 🇺🇸 US

**Who might be able to join this trial:** - You have an advanced solid tumor cancer that has stopped responding to standard treatments, has no standard treatment available, or you have chosen not to pursue standard treatment. - You are wil...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00006036 — NCIC Clinical Trials Group

NCT00006036 · NCIC Clinical Trials Group
Completed Phase 1 Est. completion 26 September 2002
🇨🇦 CA

Who might be able to join this trial: - You have been diagnosed with an advanced and/or spreading solid tumor that has been confirmed by a lab test, and standard treatments have stopped working or no curative treatment exists - Your cancer...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00423254 — Mannkind Corporation

NCT00423254 · Mannkind Corporation
Completed Phase 1 Est. completion 1 September 2009
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have an advanced solid tumour cancer that has not responded to previous treatments and has been confirmed by a tissue sample - Your cancer can be measured (f...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05461430 — Travera Inc

NCT05461430 · Travera Inc
Completed Not Applicable Est. completion 23 March 2026
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with any type of cancer (carcinoma) - You are already scheduled, as part of your normal medical care, to have fluid drained from your bod...

Trial: NCT03779399 — Medical University of Lublin

NCT03779399 · Medical University of Lublin
Completed Not Applicable Est. completion 31 May 2014
🇵🇱 PL

Who might be able to join this trial: - You are willing and able to give written consent to take part in the trial - You are between 18 and 75 years old - You have a tumor on your ovary Who may not be able to join: - You are under 18 years...

Trial: NCT07380841 — Islamabad Medical and Dental College

NCT07380841 · Islamabad Medical and Dental College
Completed Not Applicable Est. completion 11 November 2025
🇵🇰 PK

Who might be able to join this trial: - You are a woman between 18 and 40 years old - You have been diagnosed with polycystic ovary syndrome (PCOS), confirmed by having at least two of the following: irregular or absent periods, higher-than...

Trial: NCT02222922 — Pfizer

NCT02222922 · Pfizer
Completed Phase 1 Est. completion 5 November 2019
🇪🇸 ES 🇺🇸 US

**Who might be able to join this trial:** *For the every-2-weeks (Q2W) part of the trial:* - You have been diagnosed with ovarian cancer that has stopped responding to platinum-based treatment and have received 2 or fewer previous treatmen...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT04006171 — Near East University, Turkey

NCT04006171 · Near East University, Turkey
Completed Not Applicable Est. completion 1 September 2020
Cyprus

Who might be able to join this trial: - Women who have been diagnosed with Polycystic Ovary Syndrome (PCOS) based on a specific set of medical guidelines called the Rotterdam criteria (confirm with trial site) - Women who are generally heal...

Trial: NCT00944944 — Memorial Sloan Kettering Cancer Center

NCT00944944 · Memorial Sloan Kettering Cancer Center
Completed Not Applicable Est. completion 1 January 2010
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a gynecologic cancer (specifically vulvar, cervical, or uterine cancer) - You have had surgery for gynecologic cancer that included removal of lymph nodes - You curre...

Trial: NCT07441811 — Uşak University

NCT07441811 · Uşak University
Completed Not Applicable Est. completion 1 September 2022
Turkey (Türkiye)

**Who might be able to join this trial:** - You have been diagnosed with PCOS (Polycystic Ovary Syndrome) after being seen by a doctor and having blood tests and an ultrasound scan, possibly after visiting due to concerns like hair growth,...

Trial: NCT00069901 — CTI BioPharma

NCT00069901 · CTI BioPharma
Completed Phase 2 Est. completion 1 November 2005
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with stage III or IV ovarian cancer or primary peritoneal cancer (confirmed by laboratory testing of tissue samples), and have had surgery to remove as much of the tumor as...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02704832 — Institut Bergonié

NCT02704832 · Institut Bergonié
Completed Not Applicable Est. completion 31 December 2023
🇫🇷 FR

**Who might be able to join this trial:** - You are 70 years old or older - Your general health and ability to carry out daily activities falls within an acceptable range, as assessed by your doctor (using a standard 0–3 scale) - You have...

Trial: NCT02465892 — Duke University

NCT02465892 · Duke University
Completed Not Applicable Est. completion 1 October 2016
🇺🇸 US

"Who might be able to join this trial: - You currently have a pain level of 3 or higher (on a scale of 0–10), and at least one previous pain score of 3 or higher has been recorded in your medical records - You are 18 years of age or older -...

Trial: NCT02265861 — Nanjing University School of Medicine

NCT02265861 · Nanjing University School of Medicine
Completed Early Phase 1 Est. completion 1 June 2012

"Who might be able to join this trial: - You are a woman who has been identified as having Polycystic Ovary Syndrome (PCOS), diagnosed using specific criteria that look at three features: higher-than-normal male hormone levels, irregular or...

Early Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00064311 — National Institutes of Health Clinical Center (CC)

NCT00064311 · National Institutes of Health Clinical Center (CC)
Completed Phase 2
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You are receiving a specific type of stem cell transplant from a donor (called a "non-myeloablative allogeneic hematopoietic stem cell transplantation") (confir...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05840692 — Odense University Hospital

NCT05840692 · Odense University Hospital
Completed Phase 4 Est. completion 1 October 2017
🇩🇰 DK

Who might be able to join this trial: - Your BMI (body mass index) is over 25 and under 45 (confirm with trial site, as the upper limit may contain a typo in the original criteria) - You are between 18 and 45 years old - You have at least t...

Phase 4: Approved of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00021034 — Memorial Sloan Kettering Cancer Center

NCT00021034 · Memorial Sloan Kettering Cancer Center
Completed Phase 1 Est. completion 1 August 2001
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that started in the lining of the abdomen, confirmed by a tissue sample (biopsy) - Your cancer was...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03481582 — Ain Shams University

NCT03481582 · Ain Shams University
Completed Not Applicable Est. completion 1 March 2018
🇪🇬 EG

**Who might be able to join this trial:** - You are between 20 and 35 years old - Your partner's sperm test results are within normal ranges, meaning sperm count, movement, and shape all meet certain healthy levels (based on WHO 2010 stand...

Trial: NCT00113789 — Amgen

NCT00113789 · Amgen
Completed Phase 2 Est. completion 1 April 2005

**Who might be able to join this trial:** - You have been diagnosed with primary peritoneal carcinoma, epithelial ovarian cancer, or fallopian tube cancer that has come back or stopped responding to 1 or 2 previous treatments - Your cancer...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01733459 — Dexa Medica Group

NCT01733459 · Dexa Medica Group
Completed Phase 3 Est. completion 1 April 2018
🇮🇩 ID

Who might be able to join this trial: - You are a woman between 18 and 40 years old who is able to get pregnant - You have been diagnosed with polycystic ovary syndrome (PCOS), confirmed by meeting two out of three of the "Rotterdam Criteri...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00004083 — NYU Langone Health

NCT00004083 · NYU Langone Health
Completed Phase 2 Est. completion 1 December 1999
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with ovarian epithelial cancer that has come back, confirmed by a lab test on a tissue or cell sample - Your cancer may have spread to other parts of the body (metastatic...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT06238687 — Tasly Pharmaceutical Group Co., Ltd

NCT06238687 · Tasly Pharmaceutical Group Co., Ltd
Completed Phase 2 Est. completion 6 June 2025
🇨🇳 CN

**Who might be able to join this trial:** - Doctors expect you to live for more than 3 months. - You have at least one area of cancer that can be measured on a scan, and it is not in an area that has been treated with radiation. - Any side...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05767515 — Khyber Medical University Peshawar

NCT05767515 · Khyber Medical University Peshawar
Completed Not Applicable Est. completion 25 February 2024
🇵🇰 PK

**Who might be able to join this trial:** - You are a married woman between 18 and 35 years old who has been diagnosed with Polycystic Ovary Syndrome (PCOS) and are trying to get pregnant - You have been unable to conceive, either for the...

Trial: NCT00183794 — University of Southern California

NCT00183794 · University of Southern California
Completed Phase 2 Est. completion 1 May 2009
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with epithelial ovarian cancer, confirmed by a lab test of tissue samples - Your cancer has stopped responding to platinum-based chemotherapy, meaning it either got worse...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00102973 — Telik

NCT00102973 · Telik
Completed Phase 3 Est. completion 1 July 2008
🇺🇸 US

Who might be able to join this trial: - You are a woman aged 18 or older - You have been diagnosed with cancer of the ovary, fallopian tube, or the lining of the abdomen (called primary peritoneal cancer), confirmed by a lab test - Your can...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00003173 — Memorial Sloan Kettering Cancer Center

NCT00003173 · Memorial Sloan Kettering Cancer Center
Completed Phase 2 Est. completion 1 May 2003
🇺🇸 US

Who might be able to join this trial: - You have a solid cancerous tumor (not a blood cancer) that has not responded to standard treatments, or for which no standard treatment is available. - Your cancer can be measured using MRI or CT scan...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03365791 — Novartis Pharmaceuticals

NCT03365791 · Novartis Pharmaceuticals
Completed Phase 2 Est. completion 21 February 2019
🇺🇸 US

**Who might be able to join this trial:** - You have already received at least one previous treatment for your cancer, but no more than five previous treatments in total. - You have been diagnosed with a solid tumour or a type of lymphoma (...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT04369248 — Fatma ketenci gencer

NCT04369248 · Fatma ketenci gencer
Completed Not Applicable Est. completion 15 March 2020
Turkey (Türkiye)

**Who might be able to join this trial:** - Women aged between 18 and 35 years who have been diagnosed with Polycystic Ovary Syndrome (PCOS) (60 participants needed) - Healthy women aged between 18 and 35 years with a Body Mass Index (BMI)...

Trial: NCT01463969 — Gulhane School of Medicine

NCT01463969 · Gulhane School of Medicine
Completed Not Applicable
Turkey (Türkiye)

**Who might be able to join this trial:** - You have no significant health problems found during a physical check-up, apart from excess hair growth (hirsutism) - You are not currently taking any medications to lower cholesterol, control blo...

Trial: NCT01041235 — Azaya Therapeutics, Inc.

NCT01041235 · Azaya Therapeutics, Inc.
Completed Phase 1 Est. completion 1 October 2011
🇺🇸 US

**Who might be able to join this trial:** - You are able to read, understand, and sign an approved consent form agreeing to take part in the study. - You have been diagnosed with a solid tumor that has been confirmed through a laboratory ti...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03372720 — Ohio State University Comprehensive Cancer Center

NCT03372720 · Ohio State University Comprehensive Cancer Center
Completed Not Applicable Est. completion 18 December 2019
🇺🇸 US

**Who might be able to join this trial:** - You are a woman who has been diagnosed with cervical, endometrial, vaginal, vulvar, or ovarian cancer and have finished all cancer treatment at least 6 months ago - You have had no signs of cancer...

Trial: NCT06428786 — Etlik Zubeyde Hanım Women's Health Care, Training and Research Hospital

NCT06428786 · Etlik Zubeyde Hanım Women's Health Care, Training...
Completed Not Applicable Est. completion 7 October 2024
Turkey (Türkiye)

Who might be able to join this trial: - You must be at least 18 years old. - It must have been at least 1 year since you had your first period. - You must be willing to give both verbal and written agreement to take part in the trial. Who...

Trial: NCT00750386 — Hellenic Oncology Research Group

NCT00750386 · Hellenic Oncology Research Group
Completed Phase 2 Est. completion 1 March 2011
🇬🇷 GR

**Who might be able to join this trial:** - You have been diagnosed with ovarian cancer that has been confirmed through a tissue or cell sample, and you need chemotherapy as part of your treatment - You have not had chemotherapy before - Yo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02354586 — Tesaro, Inc.

NCT02354586 · Tesaro, Inc.
Completed Phase 2 Est. completion 28 February 2018
🇨🇦 CA 🇺🇸 US

**Who might be able to join this trial:** - You must be willing to have your tumor tested for a specific genetic marker (HRD) and have a blood test to check for a gene change called BRCA mutation. - If you could become pregnant, you must h...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03364673 — Dana-Farber Cancer Institute

NCT03364673 · Dana-Farber Cancer Institute
Completed Not Applicable Est. completion 31 October 2019
🇺🇸 US

Who might be able to join this trial: - You have been recently diagnosed with ovarian cancer - You finished chemotherapy no more than 6 months ago - You are able to read English - You do not have any thinking, vision, or physical/movement d...

Trial: NCT01146795 — Jason D. Wright

NCT01146795 · Jason D. Wright
Completed Phase 2 Est. completion 13 April 2015
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with, or are suspected to have, advanced-stage ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (advanced stage means it has spread widely in the abdome...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01189669 — The Adelaide and Meath Hospital

NCT01189669 · The Adelaide and Meath Hospital
Completed Not Applicable Est. completion 1 July 2008
🇮🇪 IE

**Who might be able to join this trial:** - You have been diagnosed with Polycystic Ovary Syndrome (PCOS), meaning you have fewer than 9 periods per year AND signs of higher-than-normal male hormones (such as excess body hair, acne, or thin...

Trial: NCT06007586 — Sichuan Cancer Hospital and Research Institute

NCT06007586 · Sichuan Cancer Hospital and Research Institute
Completed Phase 3 Est. completion 20 June 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with a gynecologic cancer (such as ovarian, cervical, or uterine cancer) that has been confirmed by a tissue sample (biopsy), either newly diagnosed or returned after at le...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01679483 — Asan Medical Center

NCT01679483 · Asan Medical Center
Completed Not Applicable Est. completion 1 November 2015
🇰🇷 KR

**Who might be able to join this trial:** - You have been diagnosed (confirmed by lab testing) with cancer of the cervix, uterus, ovaries, or fallopian tubes - Your cancer is at a specific stage — cervical cancer stages IA2 to IIA2, uterin...

Trial: NCT00672295 — AA Secord

NCT00672295 · AA Secord
Completed Phase 1 Est. completion 1 September 2011
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with ovarian, peritoneal, or fallopian tube cancer, confirmed by a lab test of tissue or cells - Your cancer can be measured on a scan or other test - You are over 18 year...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02122380 — Vanderbilt University

NCT02122380 · Vanderbilt University
Completed Phase 4 Est. completion 1 August 2019
🇺🇸 US

Who might be able to join this trial: - You are a woman between 18 and 40 years old - Your body mass index (BMI) is 30 or higher (considered obese range) - You have been diagnosed with polycystic ovary syndrome (PCOS) by meeting at least tw...

Phase 4: Approved of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00278343 — National Cancer Institute (NCI)

NCT00278343 · National Cancer Institute (NCI)
Completed Phase 2 Est. completion 1 June 2010
🇨🇦 CA 🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (confirmed by lab testing) that has come back or stopped responding to initial treatment. -...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03480750 — National Cheng-Kung University Hospital

NCT03480750 · National Cheng-Kung University Hospital
Completed Phase 2 Est. completion 1 October 2015

**Who might be able to join this trial:** - You have been diagnosed with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, confirmed by a tissue sample after surgery - Your cancer came back for the first time within 1 ye...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00795769 — Fred Hutchinson Cancer Center

NCT00795769 · Fred Hutchinson Cancer Center
Completed Phase 2 Est. completion 9 June 2009
🇺🇸 US

Who might be able to join this trial: - You are scheduled to receive your own previously collected stem cells back (called an autologous stem cell transplant). - You speak and understand English. - Your stem cell infusion is planned to take...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00413179 — 59th Medical Wing

NCT00413179 · 59th Medical Wing
Completed Phase 3
🇺🇸 US

Who might be able to join this trial: - You must be married - You are a woman between 18 and 40 years old who has higher than normal levels of male hormones (androgens) and wants to become pregnant - You have irregular or absent ovulation (...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03297424 — Opna Bio LLC

NCT03297424 · Opna Bio LLC
Completed Phase 1 Est. completion 7 June 2021
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with an advanced solid tumor cancer (confirmed by tissue testing) that has not responded to previous treatments, or you have a type of blood cancer called non-Hodgkin's ly...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03133286 — DxTerity Diagnostics

NCT03133286 · DxTerity Diagnostics
Completed Not Applicable Est. completion 24 February 2020
🇺🇸 US

Who might be able to join this trial: - You are 18 years of age or older, either male or female - You have a permanent home address in the United States and will be living there for the whole duration of the study - You have been diagnosed...

Trial: NCT05279768 — PT. Prodia Stem Cell Indonesia

NCT05279768 · PT. Prodia Stem Cell Indonesia
Completed Phase 2 Est. completion 20 January 2025
🇮🇩 ID

Who might be able to join this trial: - You have been diagnosed with Polycystic Ovary Syndrome (PCOS) with insulin resistance, and have irregular or absent periods. - You have signs of high male hormone (androgen) levels, confirmed by both...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00814086 — Gynecologic Oncology Group

NCT00814086 · Gynecologic Oncology Group
Completed Phase 1 Est. completion 1 July 2011
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed (confirmed by lab testing of tissue) with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer - Your cancer is at stage IIB, IIC, III, or IV - You have had...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00383279 — Wake Forest University Health Sciences

NCT00383279 · Wake Forest University Health Sciences
Completed Not Applicable Est. completion 1 February 2007
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with cervical cancer, uterine cancer, or ovarian cancer - Your diagnosis was made at least 6 months ago - Your cancer can be at any stage - You were working a paid job of at le...

Trial: NCT06534424 — Ohio State University Comprehensive Cancer Center

NCT06534424 · Ohio State University Comprehensive Cancer Center
Completed Not Applicable Est. completion 30 September 2023
🇺🇸 US

Who might be able to join this trial: - You have had genetic counseling and testing for BRCA1 and/or BRCA2 gene mutations at an approved, certified laboratory - Your genetic test results showed that you carry a known harmful gene mutation -...

Trial: NCT01360996 — Woman's

NCT01360996 · Woman's
Completed Phase 4 Est. completion 1 February 2015
🇺🇸 US

**Who might be able to join this trial:** - You are a woman between 16 and 35 years old who has been diagnosed with Polycystic Ovary Syndrome (PCOS) and are looking for a form of birth control - Your Body Mass Index (BMI) — a measure of bod...

Phase 4: Approved of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02179970 — CCTU- Cancer Theme

NCT02179970 · CCTU- Cancer Theme
Completed Phase 1 Est. completion 14 December 2018
🇬🇧 GB

**Who might be able to join this trial:** - You are 16 years old or older at the time of signing the consent form. - (For the dose escalation part of the trial) You have been diagnosed with inoperable, advanced or spread pancreatic cancer,...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03066349 — Universitair Ziekenhuis Brussel

NCT03066349 · Universitair Ziekenhuis Brussel
Completed Not Applicable Est. completion 6 April 2023
🇧🇪 BE

**Who might be able to join this trial:** - You are a woman (in a heterosexual or same-sex relationship) who is about to start fertility treatment (also called assisted reproductive technology, or ART) - You have been found to have either p...

Trial: NCT00550784 — City of Hope Medical Center

NCT00550784 · City of Hope Medical Center
Completed Phase 1 Est. completion 1 October 2014

**Who might be able to join this trial:** - You have been diagnosed with ovarian cancer, cancer of the lining of the abdomen (peritoneal cancer), or fallopian tube cancer, confirmed by a tissue test (biopsy) - Your cancer is at an advanced...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00987649 — Fujirebio Diagnostics, Inc.

NCT00987649 · Fujirebio Diagnostics, Inc.
Completed Not Applicable Est. completion 1 August 2010
🇺🇸 US

Who might be able to join this trial: - You are a woman aged 18 or older - You have a mass (a growth or lump) near your ovaries or in your pelvic area, confirmed by an imaging scan such as an ultrasound - You are already scheduled to have s...

Trial: NCT05629858 — University of Illinois at Chicago

NCT05629858 · University of Illinois at Chicago
Completed Not Applicable Est. completion 15 December 2024
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with Polycystic Ovary Syndrome (PCOS) based on having at least two of these three features: signs of high male hormones (such as excess hair, acne, or oily skin) or high h...

Trial: NCT05751252 — University Hospital, Lille

NCT05751252 · University Hospital, Lille
Completed Early Phase 1 Est. completion 9 February 2025
🇫🇷 FR

Who might be able to join this trial: - You weigh at least 51 kg (about 112 lbs) - Your Body Mass Index (BMI) is between 20 and 25 (a measure of height-to-weight ratio) - You are a woman diagnosed with Polycystic Ovary Syndrome (PCOS) with...

Early Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03735680 — OncoNano Medicine, Inc.

NCT03735680 · OncoNano Medicine, Inc.
Completed Phase 2 Est. completion 14 October 2021
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with cancer confirmed by a biopsy, and you are scheduled to have surgery to remove the tumor (either a first-time or returning tumor). - **Part 1 of the trial:** Your biops...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01540747 — AGUNCO Obstetrics and Gynecology Centre

NCT01540747 · AGUNCO Obstetrics and Gynecology Centre
Completed Phase 4
🇮🇹 IT

Who might be able to join this trial: - You have been diagnosed with Polycystic Ovary Syndrome (PCOS), a hormonal condition affecting the ovaries - Your menstrual cycle is irregular, lasting longer than 28-30 days - Your uterus has been fou...

Phase 4: Approved of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03378297 — Haukeland University Hospital

NCT03378297 · Haukeland University Hospital
Completed Early Phase 1 Est. completion 5 January 2023
🇳🇴 NO

**Who might be able to join this trial:** - You have been diagnosed with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (at least stage 3). - You are 18 years of age or older. - You have not previously receive...

Early Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT04175470 — Vejle Hospital

NCT04175470 · Vejle Hospital
Completed Phase 2 Est. completion 30 July 2024
🇩🇰 DK

**Who might be able to join this trial:** - You have been diagnosed with a specific type of cancer confirmed by lab testing — either epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. - Your cancer has stopped...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03804866 — AGC Biologics S.p.A.

NCT03804866 · AGC Biologics S.p.A.
Completed Phase 2 Est. completion 1 December 2016
🇮🇹 IT

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed (confirmed by a tissue sample/biopsy) with advanced or metastatic ovarian cancer, fallopian tube cancer, or primary peritoneal cancer - Y...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02835833 — University of Alabama at Birmingham

NCT02835833 · University of Alabama at Birmingham
Completed Phase 1 Est. completion 14 April 2018
🇺🇸 US

**Who might be able to join this trial:** - You are over 18 years old - You have been diagnosed (confirmed by tissue testing) with advanced or metastatic cancer of one of these types: kidney cancer, colorectal cancer, non-squamous non-smal...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05741554 — Hospices Civils de Lyon

NCT05741554 · Hospices Civils de Lyon
Completed Not Applicable Est. completion 1 June 2022
🇫🇷 FR

Who might be able to join this trial: - You are 18 years old or older - You have been diagnosed with low grade serous ovarian cancer according to a classification system called the MDACC classification - You have been diagnosed with Grade 1...

Trial: NCT00138242 — Floyd & Delores Jones Cancer Institute at Virginia Mason Medical Center

NCT00138242 · Floyd & Delores Jones Cancer Institute at Virginia...
Completed Phase 2
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with ovarian, fallopian tube, or peritoneal cavity cancer that has been confirmed by a tissue sample (biopsy), and your cancer is at Stage IC or higher (up to Stage IV) -...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02493972 — Centre Francois Baclesse

NCT02493972 · Centre Francois Baclesse
Completed Not Applicable Est. completion 1 July 2019
🇫🇷 FR

"Who might be able to join this trial: - You must be over 18 years of age - You must be a woman with cancer that has spread to the lining of the abdomen (peritoneum), believed to have started in the ovaries - You must have had or be plannin...

Trial: NCT00710762 — Boehringer Ingelheim

NCT00710762 · Boehringer Ingelheim
Completed Phase 2 Est. completion 1 September 2008
🇬🇧 GB

Who might be able to join this trial: - You are a woman who has been diagnosed (confirmed by lab testing) with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer of the serous type that has come back, and your canc...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01111903 — ARCAGY/ GINECO GROUP

NCT01111903 · ARCAGY/ GINECO GROUP
Completed Phase 2 Est. completion 1 December 2014
🇫🇷 FR

**Who might be able to join this trial:** - You are over 18 years old. - You have been diagnosed with epithelial ovarian cancer, fallopian tube cancer, or a related type called extra-ovarian papillary serous tumor, confirmed by a tissue sa...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00008138 — SWOG Cancer Research Network

NCT00008138 · SWOG Cancer Research Network
Completed Phase 2 Est. completion 1 September 2009

**Who might be able to join this trial:** - You have been diagnosed with stage III or IV ovarian cancer, primary peritoneal cancer, or fallopian tube cancer, confirmed by a tissue or cell sample - Your cancer is a specific type called aden...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02661932 — Erasme University Hospital

NCT02661932 · Erasme University Hospital
Completed Phase 4 Est. completion 1 March 2018
🇧🇪 BE

Who might be able to join this trial: - You are a woman with breast cancer who is under 41 years old - You have been referred to a fertility preservation service before starting chemotherapy Who may not be able to join: - Your breast cance...

Phase 4: Approved of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00673335 — UNICANCER

NCT00673335 · UNICANCER
Completed Phase 3 Est. completion 1 June 2019
🇫🇷 FR

**Who might be able to join this trial:** - You carry a harmful change (mutation) in the BRCA1 or BRCA2 gene (specifically a nonsense mutation or stop mutation) - You have chosen not to have preventive (risk-reducing) mastectomy (breast re...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03732768 — Oncoinvent Solutions AS

NCT03732768 · Oncoinvent Solutions AS
Completed Phase 1 Est. completion 30 September 2025
🇧🇪 BE 🇳🇴 NO 🇪🇸 ES

Who might be able to join this trial: - You are willing and able to give written consent and follow the study plan - You are 18 years of age or older - You have been diagnosed with epithelial ovarian cancer, fallopian tube cancer, or primar...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT04898842 — Royal Surrey County Hospital NHS Foundation Trust

NCT04898842 · Royal Surrey County Hospital NHS Foundation Trust
Completed Not Applicable Est. completion 5 October 2022
🇬🇧 GB

**Who might be able to join this trial:** - You must be 18 years of age or older - You must be able to eat and drink by mouth - You must have a confirmed diagnosis of a bowel blockage (called a small bowel obstruction) caused by colorectal...

Trial: NCT05292859 — Alaunos Therapeutics

NCT05292859 · Alaunos Therapeutics
Completed Not Applicable Est. completion 30 May 2025
🇺🇸 US

**Who might be able to join this trial:** - You must have already received a TCR-T cell treatment (a type of immune cell therapy) as part of a previous Alaunos study (such as study TCR001-201), whether you completed that study or left it ea...

Trial: NCT02159716 — University of Pennsylvania

NCT02159716 · University of Pennsylvania
Completed Phase 1 Est. completion 1 November 2015
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with one of the following cancers, confirmed by a tissue sample (biopsy): pancreatic cancer that has spread to other parts of the body; ovarian cancer or a related abdomin...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00003967 — Gynecologic Oncology Group

NCT00003967 · Gynecologic Oncology Group
Completed Phase 1 Est. completion 1 April 2006
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with ovarian, peritoneal, or fallopian tube cancer that has been confirmed by a tissue sample (biopsy), and it is one of several specific types of epithelial cell cancer (...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00038428 — Telik

NCT00038428 · Telik
Completed Phase 2 Est. completion 1 July 2005
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with ovarian cancer, confirmed by a tissue sample or biopsy - Your cancer has come back or has not fully gone away after your first course of treatment - Your cancer can be...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00283816 — University of Rochester

NCT00283816 · University of Rochester
Completed Phase 3 Est. completion 1 January 2008
🇺🇸 US

Who might be able to join this trial: - You are between 12 and 18 years old - You have irregular periods - You are overweight - You are able to swallow capsules - It has been at least 6 months since you had your first period Who may not be...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01277744 — M.D. Anderson Cancer Center

NCT01277744 · M.D. Anderson Cancer Center
Completed Phase 2 Est. completion 16 February 2018
🇺🇸 US

**Who might be able to join this trial:** - You must be at least 1 year old - You must have a type of tumor (not a carcinoma) in the abdomen or the space behind the abdomen, such as desmoplastic round cell tumor, ovarian germ cell tumor, sa...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03197077 — Universitair Ziekenhuis Brussel

NCT03197077 · Universitair Ziekenhuis Brussel
Completed Phase 3 Est. completion 31 December 2022
🇧🇪 BE

**Who might be able to join this trial:** - You are between 18 and 36 years old and are having difficulty getting pregnant and are being considered for fertility treatment - Your body mass index (BMI) is between 18 and 30 - An ultrasound sc...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05010551 — Riphah International University

NCT05010551 · Riphah International University
Completed Not Applicable Est. completion 30 May 2021
🇵🇰 PK

**Who might be able to join this trial:** - You are between 18 and 30 years old - You are married - You are a woman who has been diagnosed with Polycystic Ovary Syndrome (PCOS), meaning you have at least 2 of the following: (1) cysts on you...

Trial: NCT01040312 — Daiichi Sankyo Co., Ltd.

NCT01040312 · Daiichi Sankyo Co., Ltd.
Completed Not Applicable Est. completion 29 September 2014
🇯🇵 JP

Who might be able to join this trial: - You have been diagnosed with one or more of the following cancers: small cell lung cancer, non-small cell lung cancer, cervical cancer, ovarian cancer, or stomach (gastric) cancer - You have a specifi...

Trial: NCT00825201 — City of Hope Medical Center

NCT00825201 · City of Hope Medical Center
Completed Phase 1 Est. completion 16 January 2018
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with advanced cancer that is mainly located in the abdominal cavity (peritoneum), and it has gotten worse after previous cancer treatments, or no standard treatments exist...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02003430 — UNC Lineberger Comprehensive Cancer Center

NCT02003430 · UNC Lineberger Comprehensive Cancer Center
Completed Not Applicable Est. completion 1 October 2017
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older (there is no upper age limit) - You have been diagnosed with cervical, vaginal, vulvar, or uterine (endometrial) cancer, and radiation therapy (with or without che...

Trial: NCT00246688 — Bayer

NCT00246688 · Bayer
Completed Phase 2 Est. completion 1 June 2007

**Who might be able to join this trial:** - You are a woman aged 18 or older - You have been diagnosed with one of the following cancers: epithelial ovarian cancer, peritoneal cavity cancer, or fallopian tube cancer - You have had no more t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00420381 — Eli Lilly and Company

NCT00420381 · Eli Lilly and Company
Completed Phase 2 Est. completion 1 May 2008
🇺🇸 US

Who might be able to join this trial: - You have ovarian cancer or primary peritoneal cancer that has come back or has not gone away after treatment. - Your cancer can be measured on scans or tests, and there is at least one specific area o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00444288 — National Institute of Environmental Health Sciences (NIEHS)

NCT00444288 · National Institute of Environmental Health Science...
Completed Not Applicable
🇺🇸 US

**Who might be able to join this trial:** **For the primary twin (the twin with possible PCOS):** - You are a woman who has not yet gone through menopause and are over 18 years old - You have a living female twin sister - You have a histor...

Trial: NCT03204461 — Medical University of Vienna

NCT03204461 · Medical University of Vienna
Completed Not Applicable Est. completion 9 July 2015
🇦🇹 AT

Who might be able to join this trial: - Women who have been diagnosed with Polycystic Ovary Syndrome (PCOS) based on specific medical guidelines (called Rotterdam and NIH criteria) - Healthy women without PCOS who can take part as compariso...

Trial: NCT00381173 — Eisai Inc.

NCT00381173 · Eisai Inc.
Completed Phase 1 Est. completion 1 October 2008
🇺🇸 US

**Who might be able to join this trial:** - You have advanced cancer (ovarian, breast, colon, prostate that no longer responds to hormones, or kidney cancer) that has come back or stopped responding to treatment, and you have tried at leas...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05130515 — Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

NCT05130515 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen Unive...
Completed Phase 2 Est. completion 1 January 2023
🇨🇳 CN

**Who might be able to join this trial:** - You understood what the study involves, agreed to take part, and signed a consent form. - You are a woman between 18 and 70 years old. - Your cancer has been confirmed by a tissue test (biopsy) t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03783949 — Universitaire Ziekenhuizen KU Leuven

NCT03783949 · Universitaire Ziekenhuizen KU Leuven
Completed Phase 2 Est. completion 1 September 2023
🇦🇹 AT 🇧🇪 BE 🇫🇷 FR 🇩🇪 DE 🇮🇹 IT

**Who might be able to join this trial:** - You are a woman aged 18 or older - You have been diagnosed with a specific type of ovarian, fallopian tube, or primary peritoneal cancer (high-grade serous, high-grade endometrioid, undifferentia...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03229122 — AstraZeneca

NCT03229122 · AstraZeneca
Completed Not Applicable Est. completion 6 July 2018
🇯🇵 JP

**Who might be able to join this trial:** - You are willing and able to sign a consent form agreeing to take part in the study - You are a Japanese woman aged 20 or older - You have been newly diagnosed with epithelial ovarian cancer, prima...

Trial: NCT06164132 — Cairo University

NCT06164132 · Cairo University
Completed Not Applicable Est. completion 31 October 2023
🇪🇬 EG

Who might be able to join this trial: - You are between 18 and 40 years old. - You have been diagnosed with Polycystic Ovary Syndrome (PCOS), shown by having at least two of these three signs: irregular or absent periods, higher-than-normal...

Trial: NCT04028479 — Taproot Health

NCT04028479 · Taproot Health
Completed Not Applicable Est. completion 31 October 2024
🇺🇸 US

Who might be able to join this trial: - You (or someone acting on your behalf) are willing and able to sign a consent form agreeing to take part. - You have been diagnosed with an advanced cancer. - You are willing to receive treatment for...

Trial: NCT03778099 — King Abdulaziz University

NCT03778099 · King Abdulaziz University
Completed Phase 3 Est. completion 10 January 2020
🇸🇦 SA

**Who might be able to join this trial:** - You are a married woman between 18 and 40 years old - You are trying to get pregnant - You have been diagnosed with polycystic ovary syndrome (PCOS) based on specific medical guidelines called the...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02517554 — Abramson Cancer Center at Penn Medicine

NCT02517554 · Abramson Cancer Center at Penn Medicine
Completed Not Applicable Est. completion 1 March 2018
🇺🇸 US

Who might be able to join this trial: - You are an adult aged 18 or older - You can understand and communicate in English - You meet certain national guidelines that say you should be considered for genetic testing related to breast, ovaria...

Trial: NCT04803305 — Pfizer

NCT04803305 · Pfizer
Completed Phase 1 Est. completion 14 April 2022
🇨🇦 CA 🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with an advanced form of one of the following cancers: non-small cell lung, pancreatic, colorectal, prostate, breast, or ovarian cancer, as confirmed by your cancer doctor....

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT04630327 — Kazakh Medical University of Continuing Education

NCT04630327 · Kazakh Medical University of Continuing Education
Completed Not Applicable Est. completion 28 April 2022
🇰🇿 KZ

Who might be able to join this trial: - You are a woman between 18 and 65 years old with a main diagnosis of breast cancer, ovarian cancer, cervical cancer, colon cancer, or lung cancer. - You can speak and understand Russian or Kazakh. - Y...

Trial: NCT02996825 — City of Hope Medical Center

NCT02996825 · City of Hope Medical Center
Completed Phase 1 Est. completion 9 February 2024
🇺🇸 US

**Who might be able to join this trial:** - Your cancer must be one of the following types that has come back, and must test positive for a protein called "folate receptor alpha" (FRα) on a special lab test: ovarian, primary peritoneal, or...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00002474 — Loyola University

NCT00002474 · Loyola University
Completed Phase 2
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with ovarian epithelial cancer that has come back or stopped responding to treatment - You have previously been treated with a chemotherapy drug called cisplatin or carbop...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03041129 — University of Colorado, Denver

NCT03041129 · University of Colorado, Denver
Completed Not Applicable Est. completion 29 August 2018
🇺🇸 US

**Who might be able to join this trial:** - You are female - You are between 12 and 21 years old - You are not very physically active — meaning you do less than 2.5 hours of moderate exercise (like jogging or swimming) per week - Your BMI...

Trial: NCT01124435 — Catholic University of the Sacred Heart

NCT01124435 · Catholic University of the Sacred Heart
Completed Phase 2 Est. completion 1 September 2007
🇮🇹 IT

**Who might be able to join this trial:** - You have been diagnosed with a returning (recurrent) cancer of the ovaries, fallopian tubes, or peritoneum of a specific type (serous carcinoma), and your cancer can be measured on scans. - You h...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01738269 — Chinese PLA General Hospital

NCT01738269 · Chinese PLA General Hospital
Completed Not Applicable Est. completion 1 May 2013
🇨🇳 CN

Who might be able to join this trial: - There is enough relevant medical information available about the patient - The sample provided looks normal in appearance - There is at least 0.5 ml (a very small amount) of the sample available to us...

Trial: NCT02395341 — University of Pennsylvania

NCT02395341 · University of Pennsylvania
Completed Not Applicable Est. completion 1 February 2009
🇺🇸 US

**Who might be able to join this trial:** - You are a female who has been diagnosed with cancer and is scheduled to receive chemotherapy and/or radiation therapy. - You are between 15 and 45 years old. - You have already started your menstr...

Trial: NCT02489903 — EpicentRx, Inc.

NCT02489903 · EpicentRx, Inc.
Completed Phase 2 Est. completion 6 December 2021
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with one of the following advanced or spreading cancers, confirmed by a lab test: small cell carcinoma (at least 3rd line treatment or platinum-resistant/refractory in 2nd...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT07143682 — Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

NCT07143682 · Bangabandhu Sheikh Mujib Medical University, Dhaka...
Completed Phase 3 Est. completion 24 May 2024
Bangladesh

Who might be able to join this trial: - You are a woman with Polycystic Ovary Syndrome (PCOS) who has been having difficulty getting pregnant - You have been chosen by your doctor to receive treatment to help trigger ovulation (the release...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00216645 — Janssen Pharmaceutical K.K.

NCT00216645 · Janssen Pharmaceutical K.K.
Completed Phase 2

**Who might be able to join this trial:** - You have ovarian cancer that responded to your first treatment but then came back within 12 months. - You have received one or two rounds of chemotherapy for your ovarian cancer. - Your cancer can...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05427214 — Washington University School of Medicine

NCT05427214 · Washington University School of Medicine
Completed Not Applicable Est. completion 17 October 2024
🇺🇸 US

**Who might be able to join this trial:** - You are planning to receive radiation therapy to one of these areas: head and neck/brain, chest, abdomen, or pelvis - You are at least 18 years old - If you will be receiving contrast dye through...

Trial: NCT01697488 — Hoffmann-La Roche

NCT01697488 · Hoffmann-La Roche
Completed Not Applicable Est. completion 27 September 2019
🇩🇪 DE

Who might be able to join this trial: - For phase 1 of the study: you must be 18 years old or older - For phase 2 of the study: you must be 70 years old or older - You have been recently diagnosed with advanced ovarian cancer, fallopian tub...

Trial: NCT02178722 — Incyte Corporation

NCT02178722 · Incyte Corporation
Completed Phase 2 Est. completion 26 November 2018
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with one of these cancer types (confirmed by a tissue or cell sample): non-small cell lung cancer, melanoma, bladder/urinary tract cancer, kidney cancer, triple negative b...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03871868 — Kanuni Sultan Suleyman Training and Research Hospital

NCT03871868 · Kanuni Sultan Suleyman Training and Research Hospi...
Completed Not Applicable Est. completion 1 March 2019
Turkey (Türkiye)

**Who might be able to join this trial:** - You are a woman of reproductive age, between 25 and 50 years old - You have been found to have at least one fibroid (a non-cancerous growth in or around the womb) that is 10mm or larger in size, c...

Completed Phase 2 Est. completion 14 January 2019

**Who might be able to join this trial:** - You have signed a consent form agreeing to take part in this clinical study of tivantinib (the study drug) - You are the age specified in the original study you were enrolled in - You are well en...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00006453 — AGO Study Group

NCT00006453 · AGO Study Group
Completed Phase 3 Est. completion 1 October 2006
🇨🇦 CA 🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with ovarian cancer (a specific type called epithelial carcinoma) that cannot be fully removed by surgery or treated with radiation to cure it - Your cancer has come back o...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT04610957 — FAlbasri

NCT04610957 · FAlbasri
Completed Not Applicable Est. completion 1 January 2019
🇪🇬 EG

**Who might be able to join this trial:** - You are between 18 and 35 years old and have been having difficulty getting pregnant, whether for the first time or after a previous pregnancy. **Who may not be able to join:** - You are outside...

Trial: NCT01832116 — University Medical Center Groningen

NCT01832116 · University Medical Center Groningen
Completed Phase 1 Est. completion 1 May 2014
🇳🇱 NL

Who might be able to join this trial: - You must be 18 years of age or older - You must be well enough to carry out light activity and care for yourself (your doctor can assess this using a standard fitness scale) - You must have been diagn...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00465725 — Poniard Pharmaceuticals

NCT00465725 · Poniard Pharmaceuticals
Completed Phase 1 Est. completion 1 July 2009
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with a solid tumour cancer (not a blood cancer), confirmed by a tissue sample or biopsy. - Your doctor believes there are no standard treatments left available for you, and tha...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01644825 — National Cancer Institute, Naples

NCT01644825 · National Cancer Institute, Naples
Completed Phase 2 Est. completion 1 May 2014
🇮🇹 IT

**Who might be able to join this trial:** - You have been diagnosed with ovarian cancer at stage IC, II, III, or IV, confirmed by a tissue or cell sample - Your cancer got worse during your first round of chemotherapy, or it came back withi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02635672 — Vincerx Pharma, Inc.

NCT02635672 · Vincerx Pharma, Inc.
Completed Phase 1 Est. completion 11 November 2024
🇨🇱 CL 🇪🇸 ES 🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older - You have a solid tumor or an aggressive type of blood cancer called NHL that has been confirmed by lab testing, and your cancer either has not responded to or you h...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00287885 — Masonic Cancer Center, University of Minnesota

NCT00287885 · Masonic Cancer Center, University of Minnesota
Completed Phase 1 Est. completion 1 December 2008

**Who might be able to join this trial:** - You have been diagnosed with an advanced gynecological cancer (such as ovarian, cervical, or uterine cancer) that has been confirmed by a tissue sample (biopsy), and the cancer has not responded...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02028117 — Akamis Bio

NCT02028117 · Akamis Bio
Completed Phase 1 Est. completion 19 November 2019
🇪🇸 ES 🇬🇧 GB

**Who might be able to join this trial:** - You are willing and able to give written consent and follow the study rules - You are 18 years old or older - You have been diagnosed with ovarian, fallopian tube, or primary peritoneal cancer (c...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00315692 — Fujirebio Diagnostics, Inc.

NCT00315692 · Fujirebio Diagnostics, Inc.
Completed Not Applicable
🇺🇸 US

Who might be able to join this trial: - You are a woman (aged 18 or older, either before or after menopause) who has been scheduled for abdominal or keyhole surgery because a pelvic mass was found - The pelvic mass can be a simple, complex,...

Trial: NCT06582849 — Washington University School of Medicine

NCT06582849 · Washington University School of Medicine
Completed Not Applicable Est. completion 8 August 2025
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older. - You are planning to receive, or are already receiving, a longer course of radiation therapy aimed at curing your cancer (this includes radiation given before surg...

Trial: NCT00486707 — M.D. Anderson Cancer Center

NCT00486707 · M.D. Anderson Cancer Center
Completed Not Applicable Est. completion 1 October 2008
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with ovarian cancer. - You are at least 18 years old at the time of signing up for the trial. - You are able to read and write in English. Who may not be able to join: - You a...

Trial: NCT02146313 — Genentech, Inc.

NCT02146313 · Genentech, Inc.
Completed Phase 1 Est. completion 18 June 2018
🇺🇸 US

**Who might be able to join this trial:** - Doctors expect you to live for at least 12 weeks - You are able to carry out normal daily activities with little or no limitation (confirm with trial site for exact definition) - You have at leas...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01384097 — Charite University, Berlin, Germany

NCT01384097 · Charite University, Berlin, Germany
Completed Not Applicable Est. completion 1 February 2011
🇩🇪 DE

Who might be able to join this trial: - You are 18 years old or older - You are having one of the following planned surgeries at the Charité - University Medicine Berlin, Campus Virchow Clinic: hip fracture repair, a type of colon surgery (...

Trial: NCT00102414 — AGO Study Group

NCT00102414 · AGO Study Group
Completed Phase 3

**Who might be able to join this trial:** - You have been diagnosed with ovarian cancer (confirmed by laboratory testing of tissue) that has come back or gotten worse - Your cancer continued to return or grow more than 6 months after you fi...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00002580 — Scottish Cancer Therapy Network

NCT00002580 · Scottish Cancer Therapy Network
Completed Phase 3
🇬🇧 GB

**Who might be able to join this trial:** - You have been diagnosed with invasive breast cancer in one breast, confirmed by a tissue sample (biopsy) - Your cancer is at an early to moderate stage, meaning it may or may not have spread to n...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00003657 — Dana-Farber Cancer Institute

NCT00003657 · Dana-Farber Cancer Institute
Completed Phase 2 Est. completion 1 November 2000
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a cancer that has been confirmed by a tissue sample (biopsy). - Your cancer has spread to other parts of the body or cannot be removed by surgery. - You may be respond...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01427595 — University of Virginia

NCT01427595 · University of Virginia
Completed Not Applicable Est. completion 17 January 2015
🇺🇸 US

**Who might be able to join this trial:** - Girls between the ages of 10 and 17 - Girls who have higher-than-normal levels of male hormones (specifically a hormone called free testosterone) for their stage of puberty - Girls whose kidneys a...

Trial: NCT06844903 — Kafrelsheikh University

NCT06844903 · Kafrelsheikh University
Completed Not Applicable Est. completion 26 June 2025
🇪🇬 EG

**Who might be able to join this trial:** - You are an adult between 18 and 35 years old. - You are willing and able to stop taking any medications that could affect the study results during the study period. - Your body mass index (BMI) is...

Trial: NCT01422265 — Genentech, Inc.

NCT01422265 · Genentech, Inc.
Completed Not Applicable Est. completion 1 April 2015
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma (confirmed by a tissue sample/biopsy), and it came back more than 6 months after you finished...

Trial: NCT00640224 — Silva Arslanian

NCT00640224 · Silva Arslanian
Completed Phase 4 Est. completion 1 July 2015
🇺🇸 US

Who might be able to join this trial: - Be between 10 and 20 years old - Have reached a certain stage of puberty (mid-to-late puberty) and have already had their first menstrual period (confirm with trial site) - Have a BMI (body weight rel...

Phase 4: Approved of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01826227 — Memorial Sloan Kettering Cancer Center

NCT01826227 · Memorial Sloan Kettering Cancer Center
Completed Not Applicable Est. completion 1 December 2016
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (confirmed by laboratory testing), not including low-risk/borderline tumors — all stages, grades, and t...

Trial: NCT04971304 — Catherine M. Lockhart

NCT04971304 · Catherine M. Lockhart
Completed Not Applicable Est. completion 30 September 2022

**Who might be able to join this trial:** - You are 20 years old or older - You have been diagnosed with one of the following cancers: lung, breast, colon, ovarian, pancreatic, testicular, cervical, uterine, or non-Hodgkin's lymphoma (NHL)...

Trial: NCT01440504 — Centre Francois Baclesse

NCT01440504 · Centre Francois Baclesse
Completed Not Applicable Est. completion 1 January 2013
🇫🇷 FR

Who might be able to join this trial: - You must be 18 years of age or older - You must have ovarian cancer with at least five tumor tissue samples available that were not needed to make your diagnosis (taken from other tumor areas) - You m...

Trial: NCT05231746 — STCube, Inc.

NCT05231746 · STCube, Inc.
Completed Phase 1 Est. completion 29 February 2024
🇰🇷 KR 🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older - You are willing and able to give your signed agreement to take part in the study - You have at least one tumour or lesion that can be measured on a scan, based on s...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00020267 — National Cancer Institute (NCI)

NCT00020267 · National Cancer Institute (NCI)
Completed Phase 1
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with one of these cancers that has spread to other parts of the body: skin melanoma, eye melanoma, colorectal cancer, non-small cell lung cancer, breast cancer, or sarcoma...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05868889 — Grupo Español de Investigación en Cáncer de Ovario

NCT05868889 · Grupo Español de Investigación en Cáncer de Ovario
Completed Not Applicable Est. completion 10 June 2022
🇪🇸 ES

**Who might be able to join this trial:** - You must agree to take part by signing a consent form (or, in some cases where this is not possible, the researcher may sign a form confirming consent was not obtainable) - You must be a woman age...

Trial: NCT01770353 — Ipsen

NCT01770353 · Ipsen
Completed Phase 1 Est. completion 2 October 2018
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with a solid tumor (a type of cancer that forms a solid mass), confirmed by laboratory testing - Your cancer has spread to other parts of the body (metastatic disease) - You ar...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03717935 — University of Colorado, Denver

NCT03717935 · University of Colorado, Denver
Completed Not Applicable Est. completion 14 January 2022
🇺🇸 US

**Who might be able to join this trial:** - You are female - You are between 12 and 21 years old - You exercise less than 2 hours per week of moderate activity (such as jogging or swimming) - Your BMI is at or above the 90th percentile for...

Trial: NCT01809379 — Ruhr University of Bochum

NCT01809379 · Ruhr University of Bochum
Completed Phase 2 Est. completion 1 March 2014
🇩🇪 DE

Who might be able to join this trial: - You have received at least 2 different chemotherapy treatments in the past - You have ovarian cancer that has come back after previous treatment - You are able to move around independently (not bedrid...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT06789224 — Lindis Bloodcare GmbH

NCT06789224 · Lindis Bloodcare GmbH
Completed Not Applicable Est. completion 25 November 2023
🇩🇪 DE

**Who might be able to join this trial:** - Your doctor (the investigator) has determined that you are a suitable candidate for a procedure where your own blood is collected and cleaned during surgery for possible reuse. - You have been di...

Trial: NCT00003670 — Eli Lilly and Company

NCT00003670 · Eli Lilly and Company
Completed Phase 2
🇺🇸 US

**Who might be able to join this trial:** - You are a woman aged 18 or older with ovarian cancer (a specific type called epithelial ovarian cancer) or a related cancer called primary peritoneal cancer, confirmed by laboratory testing of tu...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03249142 — ARCAGY/ GINECO GROUP

NCT03249142 · ARCAGY/ GINECO GROUP
Completed Phase 2 Est. completion 31 December 2024
🇫🇷 FR

**Who might be able to join this trial:** - You must be a woman aged 18 or older. - You must be willing and able to sign a consent form and follow the treatment and check-up schedule. - You must have been recently diagnosed with a specific...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01869400 — PharmaMar, Spain

NCT01869400 · PharmaMar, Spain
Completed Not Applicable Est. completion 1 December 2016
🇩🇪 DE

Who might be able to join this trial: - You must be a woman aged 18 or older (there is no maximum age limit) - You must have ovarian cancer that came back after treatment and previously responded well to platinum-based chemotherapy - You mu...

Trial: NCT02743637 — SynDevRx, Inc.

NCT02743637 · SynDevRx, Inc.
Completed Phase 1 Est. completion 16 December 2019
🇺🇸 US

Who might be able to join this trial: - You have at least one area of disease that can be seen and measured on a scan (such as an X-ray, CT, or MRI). - You are generally able to carry out everyday activities and care for yourself, with litt...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00073541 — EMD Serono

NCT00073541 · EMD Serono
Completed Phase 2 Est. completion 1 March 2004
🇺🇸 US

**Who might be able to join this trial:** - You have ovarian cancer (or a related cancer called primary peritoneal cancer) that has come back after previous treatment, and the cancer did not respond well to platinum-based chemotherapy - Lab...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03151005 — Xinqiao Hospital of Chongqing

NCT03151005 · Xinqiao Hospital of Chongqing
Completed Phase 4 Est. completion 1 April 2021
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with Polycystic Ovary Syndrome (PCOS) based on having at least two of these three signs: irregular periods, higher-than-normal male hormones (from a blood test or physical...

Phase 4: Approved of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01370122 — Abramson Cancer Center at Penn Medicine

NCT01370122 · Abramson Cancer Center at Penn Medicine
Completed Not Applicable Est. completion 1 October 2012
🇺🇸 US

**Who might be able to join this trial:** - You are a woman who had surgery for a gynecologic cancer at one of three hospitals in center city Philadelphia (HUP or Pennsylvania Hospital), and your medical records from the time of your diagno...

Trial: NCT03760926 — May Health

NCT03760926 · May Health
Completed Not Applicable Est. completion 2 September 2023
🇧🇪 BE 🇫🇷 FR 🇬🇧 GB

**Who might be able to join this trial:** - You are a woman aged between 18 and 40 years old - You have been diagnosed with Polycystic Ovary Syndrome (PCOS), confirmed by at least 2 of these 3 signs: irregular or infrequent periods (35+ da...

Trial: NCT02713386 — NRG Oncology

NCT02713386 · NRG Oncology
Completed Phase 2 Est. completion 30 September 2021
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with (or are strongly suspected to have) advanced ovarian, fallopian tube, or peritoneal cancer (stage III or IV) that has not been treated yet, and your doctors plan to g...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03571841 — Dana-Farber Cancer Institute

NCT03571841 · Dana-Farber Cancer Institute
Completed Not Applicable Est. completion 1 December 2019
🇺🇸 US

**Who might be able to join this trial:** - You are a woman who has had breast cancer and are currently taking medication to suppress your ovaries' hormone production - You are 50 years old or younger - You have not had any active cancer tr...

Trial: NCT01396369 — University of Kansas Medical Center

NCT01396369 · University of Kansas Medical Center
Completed Early Phase 1 Est. completion 1 December 2013
🇺🇸 US

Who might be able to join this trial: - You are a woman between 18 and 40 years old - You have been diagnosed with Polycystic Ovary Syndrome (PCOS), shown by having fewer than 9 periods per year or periods more than 40 days apart, a score a...

Early Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00989131 — Oasmia Pharmaceutical AB

NCT00989131 · Oasmia Pharmaceutical AB
Completed Phase 3 Est. completion 1 October 2013
Belarus 🇧🇪 BE 🇧🇬 BG 🇭🇷 HR 🇨🇿 CZ

**Who might be able to join this trial:** - You have been diagnosed with ovarian cancer, primary peritoneal cancer, or fallopian tube cancer, confirmed by a tissue or cell sample test - Your cancer came back more than 6 months after finish...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01155258 — University of Southern California

NCT01155258 · University of Southern California
Completed Phase 1 Est. completion 1 January 2013
🇺🇸 US

**Who might be able to join this trial:** - You have a confirmed cancer that has spread or cannot be removed by surgery, and standard treatments no longer exist or are no longer working — specifically cancers of the lung, breast, ovary, ce...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00253708 — Beth Israel Deaconess Medical Center

NCT00253708 · Beth Israel Deaconess Medical Center
Completed Not Applicable Est. completion 1 January 2013
🇺🇸 US

Who might be able to join this trial: - You have a solid cancer (a tumor-based cancer, not a blood cancer) that has spread to other parts of your body. - You are currently receiving cancer treatment at Beth Israel Deaconess Medical Center (...

Trial: NCT01381861 — Tracon Pharmaceuticals Inc.

NCT01381861 · Tracon Pharmaceuticals Inc.
Completed Phase 2 Est. completion 1 August 2012
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with ovarian, fallopian tube, or primary peritoneal cancer that has come back after previous treatment - Your cancer can be measured using medical scans, with at least one...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01521325 — Morphotek

NCT01521325 · Morphotek
Completed Phase 1 Est. completion 1 March 2013
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older (male or female) - You have been diagnosed with a cancer that has been confirmed by lab testing to express a protein called mesothellin - Your cancer can be measu...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02737787 — Memorial Sloan Kettering Cancer Center

NCT02737787 · Memorial Sloan Kettering Cancer Center
Completed Phase 1 Est. completion 6 April 2023
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with ovarian, fallopian tube, or primary peritoneal cancer, confirmed by a pathology review at Memorial Sloan Kettering (MSK). - Your cancer came back at least once, but y...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05394935 — Cardiff Metropolitan University

NCT05394935 · Cardiff Metropolitan University
Completed Not Applicable Est. completion 25 May 2024
🇬🇧 GB

Who might be able to join this trial: - You have been diagnosed with Polycystic Ovary Syndrome (PCOS) using any recognised diagnostic method. - You are currently inactive, meaning you do less than 40 minutes of structured exercise per week....

Trial: NCT03085238 — MTrap, Inc.

NCT03085238 · MTrap, Inc.
Completed Not Applicable Est. completion 12 September 2018
🇪🇸 ES

**Who might be able to join this trial:** - You are a woman aged 18 or older - You have been diagnosed with Stage IIIC ovarian cancer - Your cancer is a specific type called high-grade serous carcinoma - You meet one of these surgery/treatm...

Trial: NCT00443196 — Pierian Biosciences

NCT00443196 · Pierian Biosciences
Completed Phase 3
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (a cancer affecting the lining of the abdomen). - You are newly diagnosed and have never had chemo...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01932125 — Hoffmann-La Roche

NCT01932125 · Hoffmann-La Roche
Completed Phase 4 Est. completion 18 June 2025
🇮🇳 IN

Who might be able to join this trial: - You have been prescribed bevacizumab, or are already being treated with it, for advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (at a stage classified as IIIb, IIIc, or IV...

Phase 4: Approved of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01357161 — Merck Sharp & Dohme LLC

NCT01357161 · Merck Sharp & Dohme LLC
Completed Phase 2 Est. completion 8 August 2016

**Who might be able to join this trial:** - You have been diagnosed with ovarian, fallopian tube, or primary peritoneal cancer (confirmed by a tissue sample), and it is not a low-grade or borderline type. - Your cancer has come back or gott...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00862355 — Sun Pharma Advanced Research Company Limited

NCT00862355 · Sun Pharma Advanced Research Company Limited
Completed Phase 1 Est. completion 1 December 2010
🇮🇳 IN

**Who might be able to join this trial:** - You must be available for the full length of the study and willing to follow all study requirements. - You must have an official diagnosis of ovarian cancer and be suitable to receive a specific d...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03026062 — M.D. Anderson Cancer Center

NCT03026062 · M.D. Anderson Cancer Center
Completed Phase 2 Est. completion 11 September 2025
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older. - You are able to carry out normal daily activities, or have only minor limitations due to your illness (confirm with trial site). - Your blood counts and organ...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02013492 — William Carson

NCT02013492 · William Carson
Completed Early Phase 1 Est. completion 12 June 2015
🇺🇸 US

**Who might be able to join this trial:** - You have a solid tumor cancer that has come back in the same area or spread to other parts of the body, confirmed by a tissue or cell test. - The first 10 spots in the trial are open to any cance...

Early Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02259699 — University of California, Irvine

NCT02259699 · University of California, Irvine
Completed Not Applicable Est. completion 31 December 2016
🇺🇸 US

Here is the eligibility information for this clinical trial explained in plain English: **Who might be able to join this trial:** - You have been diagnosed with stage III ovarian cancer that was treated with surgery to remove as much of th...

Trial: NCT00478387 — University of Pennsylvania

NCT00478387 · University of Pennsylvania
Completed Not Applicable Est. completion 1 June 2011
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with epithelial ovarian cancer or primary peritoneal carcinoma, confirmed by a tissue sample (biopsy). - You finished chemotherapy no more than 6 months ago. - You have Sta...

Trial: NCT03754569 — Assistance Publique - Hôpitaux de Paris

NCT03754569 · Assistance Publique - Hôpitaux de Paris
Completed Not Applicable Est. completion 10 July 2019
🇫🇷 FR

Who might be able to join this trial: - You must be over 18 years old and a French national - You have been diagnosed with a type of ovarian or fallopian tube cancer that starts in the surface tissue (epithelial cancer) - You have had surge...

Trial: NCT01872078 — AstraZeneca

NCT01872078 · AstraZeneca
Completed Phase 2 Est. completion 1 July 2014
🇩🇪 DE 🇬🇧 GB 🇺🇸 US

**Who might be able to join this trial:** - You are a woman between 18 and 45 years old (inclusive) - You have suitable veins that can be used for blood draws or an IV line - Your body mass index (BMI) is between 18 and 40 (a measure based...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02568488 — Ahmed Maged

NCT02568488 · Ahmed Maged
Completed Phase 4 Est. completion 1 September 2015

**Who might be able to join this trial:** - You are a woman diagnosed with Polycystic Ovary Syndrome (PCOS) and are not currently pregnant. - You have a history of irregular or very infrequent periods — for example, cycles longer than 35 da...

Phase 4: Approved of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03131492 — Hospital Universitari Vall d'Hebron Research Institute

NCT03131492 · Hospital Universitari Vall d'Hebron Research Insti...
Completed Not Applicable Est. completion 31 December 2020
🇪🇸 ES

Who might be able to join this trial: - You have been diagnosed with ovarian cancer at stage 3 or stage 4 - Your treatment requires surgery that includes removing part of the intestine Who may not be able to join: - You have an infection t...

Trial: NCT02460445 — Manuel Luque Ramírez

NCT02460445 · Manuel Luque Ramírez
Completed Not Applicable Est. completion 1 June 2020
🇪🇸 ES

**Who might be able to join this trial:** - You are a woman who has not yet gone through menopause and has been diagnosed with higher-than-normal levels of male hormones (such as testosterone), either due to Polycystic Ovary Syndrome (PCOS...

Trial: NCT03430700 — University College, London

NCT03430700 · University College, London
Completed Phase 2 Est. completion 3 December 2025
🇬🇧 GB

**Who might be able to join this trial:** - You have been diagnosed with high-grade recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (not the mucinous type) - You are 18 years of age or older - You are willing...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01333748 — Centre Francois Baclesse

NCT01333748 · Centre Francois Baclesse
Completed Phase 2 Est. completion 1 June 2012
🇫🇷 FR

**Who might be able to join this trial:** *For patients:* - You are a woman who has been diagnosed with breast cancer and/or ovarian cancer, and your doctors believe your cancer may run in the family - You have already been tested for chan...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00415181 — University of Southern Denmark

NCT00415181 · University of Southern Denmark
Completed Not Applicable Est. completion 1 January 2009
🇩🇰 DK 🇸🇪 SE

Who might be able to join this trial: - You have been diagnosed with invasive ovarian cancer, fallopian tube cancer, or peritoneal cancer, confirmed by a tissue sample (biopsy) - Your cancer is at a certain stage or type: either a more adva...

Trial: NCT00288821 — UMC Utrecht

NCT00288821 · UMC Utrecht
Completed Not Applicable Est. completion 1 March 2009
🇳🇱 NL

Who might be able to join this trial: - You have been diagnosed with cervical cancer at an early to moderately advanced stage (stage Ia2, Ib, or IIa) - You have been diagnosed with endometrial (womb) cancer at stage I (high risk) or stage I...

Trial: NCT00227721 — Robert Morris

NCT00227721 · Robert Morris
Completed Phase 2 Est. completion 1 June 2011
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with ovarian cancer or peritoneal cavity cancer that was confirmed by a tissue sample (biopsy) - Your cancer came back or stopped responding after your first treatment, wh...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT06887296 — University Hospital, Toulouse

NCT06887296 · University Hospital, Toulouse
Completed Not Applicable Est. completion 24 October 2025
🇫🇷 FR

"Who might be able to join this trial: **For the PCOS group:** - You must be an adult - You must have been medically diagnosed with polycystic ovarian syndrome (PCOS) - You must have no objection to taking part in the study **For the cont...

Trial: NCT05340634 — Margan Biotech

NCT05340634 · Margan Biotech
Completed Phase 4 Est. completion 2 February 2022
🇪🇸 ES

**Who might be able to join this trial:** - You are a woman who has recently been diagnosed with Polycystic Ovary Syndrome (PCOS), with at least 2 of the following: irregular periods (cycles shorter than 21 days, longer than 35 days, any c...

Phase 4: Approved of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02766582 — Medical College of Wisconsin

NCT02766582 · Medical College of Wisconsin
Completed Phase 2 Est. completion 1 May 2022
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with advanced stage III or IV ovarian, fallopian tube, or primary peritoneal cancer (a specific type called "epithelial"). - You are 18 years of age or older. - You are wi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00956267 — Mansoura University

NCT00956267 · Mansoura University
Completed Not Applicable Est. completion 1 March 2009
🇪🇬 EG

Who might be able to join this trial: - You have been diagnosed with Polycystic Ovary Syndrome (PCOS) and have not responded to treatment with a medication called Clomiphene Citrate (a common fertility drug) (confirm with trial site) Who m...

Trial: NCT00408590 — Mayo Clinic

NCT00408590 · Mayo Clinic
Completed Phase 1 Est. completion 1 August 2012
🇺🇸 US

**Who might be able to join this trial:** - You must be 18 years of age or older. - You must have ovarian cancer or primary peritoneal cancer that has come back, continued to grow, or not gone away after being treated with platinum-based a...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01743469 — Ipsen

NCT01743469 · Ipsen
Completed Phase 2 Est. completion 1 December 2014
🇧🇪 BE 🇨🇦 CA 🇫🇷 FR 🇪🇸 ES 🇬🇧 GB

**Who might be able to join this trial:** **All patients must meet these criteria:** - You are willing and able to give written consent and follow the study rules and procedures. - You are 18 years of age or older. - You are generally able...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00058552 — Genentech, Inc.

NCT00058552 · Genentech, Inc.
Completed Phase 2 Est. completion 1 July 2004

**Who might be able to join this trial:** - You are willing to sign a consent form agreeing to take part in the study - You are willing to have a tumor biopsy taken, and your tumor is in a location that can be safely biopsied (first group...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00484705 — Göteborg University

NCT00484705 · Göteborg University
Completed Not Applicable Est. completion 1 October 2008
🇸🇪 SE

Who might be able to join this trial: - You have been diagnosed with Polycystic Ovary Syndrome (PCOS), confirmed by an ultrasound showing at least one ovary with the typical cyst pattern, according to standard Rotterdam guidelines - You als...

Trial: NCT02389088 — University of California, San Diego

NCT02389088 · University of California, San Diego
Completed Not Applicable Est. completion 1 January 2013

Who might be able to join this trial: - You have been diagnosed with Polycystic Ovary Syndrome (PCOS), based on having irregular periods and signs (either from symptoms or blood tests) of higher-than-normal male hormone levels. - You have n...

Trial: NCT00390234 — National Cancer Institute (NCI)

NCT00390234 · National Cancer Institute (NCI)
Completed Phase 2 Est. completion 1 September 2011
🇨🇦 CA 🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a soft tissue sarcoma (a type of cancer) of the female reproductive system, specifically uterine leiomyosarcoma, malignant mixed mullerian tumor/carcinosarcoma, or a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05322889 — Dr. Frank Behrens

NCT05322889 · Dr. Frank Behrens
Completed Phase 2 Est. completion 4 October 2022
🇩🇪 DE

**Who might be able to join this trial:** - You have been diagnosed with ovarian or breast cancer, and your doctor has planned for you to receive a chemotherapy drug called paclitaxel as part of your standard care - You are a woman aged 18...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03082976 — AstraZeneca

NCT03082976 · AstraZeneca
Completed Not Applicable Est. completion 24 July 2019
🇦🇪 AE

Who might be able to join this trial: - You are willing to sign a consent form agreeing to take part in the study - You are a woman aged 18 or older - You have been diagnosed with ovarian cancer or primary peritoneal cancer, confirmed throu...

Trial: NCT03959761 — Hospices Civils de Lyon

NCT03959761 · Hospices Civils de Lyon
Completed Phase 2 Est. completion 3 October 2022
🇫🇷 FR

**Who might be able to join this trial:** - You are at least 18 years old. - You are able and willing to sign a consent form and follow the study schedule. - You have been diagnosed (confirmed by lab testing) with ovarian cancer, peritonea...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02086526 — Mayo Clinic

NCT02086526 · Mayo Clinic
Completed Phase 1 Est. completion 20 November 2016
🇺🇸 US

Who might be able to join this trial: - You have a Body Mass Index (BMI) of 25 or higher (considered overweight or obese). - You have been diagnosed with Polycystic Ovary Syndrome (PCOS), specifically having fewer than 9 periods per year AN...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT07635082 — Eman Basuni Ebrahim Mowad

NCT07635082 · Eman Basuni Ebrahim Mowad
Completed Phase 2 Est. completion 1 June 2025
🇪🇬 EG

**Who might be able to join this trial:** - Women who have been diagnosed with polycystic ovary syndrome (PCOS) using a standard set of medical guidelines called the Rotterdam criteria. - Women whose PCOS has not responded to a fertility me...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03054298 — University of Pennsylvania

NCT03054298 · University of Pennsylvania
Completed Phase 1 Est. completion 9 November 2023
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with one of the following cancers, confirmed by a tissue sample (biopsy): lung adenocarcinoma (that has spread or come back), a type of ovarian, peritoneal, or fallopian t...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00001944 — National Cancer Institute (NCI)

NCT00001944 · National Cancer Institute (NCI)
Completed Phase 1
🇺🇸 US

**Who might be able to join this trial:** - You must be 18 years of age or older. - Your cancer must have been confirmed by a tissue or cell sample (biopsy or lab test), and there must be no known standard treatment available that could ext...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03748186 — Sutro Biopharma, Inc.

NCT03748186 · Sutro Biopharma, Inc.
Completed Phase 1 Est. completion 4 June 2024
🇪🇸 ES 🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - Your cancer can be measured on a scan (confirm with trial site) - You are fairly active and able to care for yourself, with only mild limitations on daily activ...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01675310 — Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes

NCT01675310 · Instituto Nacional de Perinatologia Isidro Espinos...
Completed Phase 4 Est. completion 1 December 2014
🇲🇽 MX

**Who might be able to join this trial:** - You are a woman of Mexican origin who is less than 16 weeks pregnant - You have had a normal blood sugar test (a glucose tolerance test using 75g over 2 hours) - You meet **3 or more** of the foll...

Phase 4: Approved of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00849199 — NYU Langone Health

NCT00849199 · NYU Langone Health
Completed Not Applicable Est. completion 1 January 2018
🇺🇸 US

Who might be able to join this trial: - You are a woman or a man aged 18 or older - You have a family history of breast cancer, ovarian cancer, or both - You have personally had breast or ovarian cancer, or you or a family member have teste...

Trial: NCT00072410 — Ludwig Institute for Cancer Research

NCT00072410 · Ludwig Institute for Cancer Research
Completed Phase 1 Est. completion 1 May 2005
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a specific type of ovarian cancer (non-mucinous ovarian adenocarcinoma), confirmed by a lab test on tissue. - Your ovarian cancer (Stage 3) has come back or has not f...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT06549816 — Seagen, a wholly owned subsidiary of Pfizer

NCT06549816 · Seagen, a wholly owned subsidiary of Pfizer
Completed Phase 1 Est. completion 18 November 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with a type of cancer that has spread or cannot be surgically removed, confirmed by a lab test, and it must be one of these specific cancer types: non-small cell lung canc...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05751629 — Tesaro, Inc.

NCT05751629 · Tesaro, Inc.
Completed Phase 2 Est. completion 1 April 2022
🇺🇸 US

**Who might be able to join this trial:** - Your ovarian cancer got worse within 6 months of finishing at least 4 cycles of a platinum-based chemotherapy treatment (note: if your cancer progressed *during* or within 4 weeks of completing y...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT06274541 — Cancer Trials Ireland

NCT06274541 · Cancer Trials Ireland
Completed Not Applicable Est. completion 17 December 2025
🇮🇪 IE

**Who might be able to join this trial:** - You have been diagnosed with a specific type of ovarian, fallopian tube, or peritoneal cancer called high grade serous or high grade endometrioid carcinoma, at any stage (I through IV) - You are n...

Trial: NCT01940666 — Taipei Medical University WanFang Hospital

NCT01940666 · Taipei Medical University WanFang Hospital
Completed Not Applicable Est. completion 1 March 2013
🇹🇼 TW

**Who might be able to join this trial:** - Women who have higher-than-normal levels of male hormones (androgens), measured by at least one of four specific hormone tests (total testosterone, androstenedione, free androgen index, or DHEAS)...

Trial: NCT01464398 — Milton S. Hershey Medical Center

NCT01464398 · Milton S. Hershey Medical Center
Completed Not Applicable Est. completion 1 June 2014
🇺🇸 US

Who might be able to join this trial: - You are a woman aged 18 years or older - You have a body mass index (BMI) of 25 or higher, meaning you are considered overweight or obese Who may not be able to join: - You are currently pregnant - Y...

Trial: NCT00003358 — Memorial Sloan Kettering Cancer Center

NCT00003358 · Memorial Sloan Kettering Cancer Center
Completed Phase 1 Est. completion 1 January 2001
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, confirmed by a tissue sample examined in a lab - You have already had surgery to remov...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01684878 — Hoffmann-La Roche

NCT01684878 · Hoffmann-La Roche
Completed Phase 3 Est. completion 30 January 2015
🇦🇹 AT 🇧🇪 BE 🇩🇰 DK 🇫🇷 FR 🇩🇪 DE

**Who might be able to join this trial:** - You have been diagnosed with ovarian cancer, primary peritoneal cancer, and/or fallopian tube cancer (confirmed by lab testing of tissue or cells) that has stopped responding to platinum-based ch...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT04539327 — Grupo Español de Investigación en Cáncer de Ovario

NCT04539327 · Grupo Español de Investigación en Cáncer de Ovario
Completed Not Applicable Est. completion 31 July 2021
🇪🇸 ES

**Who might be able to join this trial:** - You must be willing to sign a consent form if you are able to be contacted and are alive (in some cases, consent may not be needed for patients who cannot be reached, depending on legal and ethica...

Trial: NCT03043924 — University Hospital, Lille

NCT03043924 · University Hospital, Lille
Completed Not Applicable Est. completion 15 April 2022
🇫🇷 FR

**Who might be able to join this trial:** - You are between 19 and 30 years old - Your body mass index (a measure of body weight relative to height) is between 18 and 25 - You are willing and able to give your written agreement to take par...

Trial: NCT01484015 — Wake Forest University Health Sciences

NCT01484015 · Wake Forest University Health Sciences
Completed Phase 1 Est. completion 1 June 2012
🇺🇸 US

**Who might be able to join this trial:** - Your blood has very low levels of infection-fighting white blood cells (called neutrophils), or your levels are expected to drop very low soon - You currently have a fever above 38.0°C (100.4°F) -...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01457209 — Göteborg University

NCT01457209 · Göteborg University
Completed Phase 1 Est. completion 1 December 2013
🇸🇪 SE

Who might be able to join this trial: - Your Body Mass Index (BMI) is between 25 and 35 (overweight to moderately obese range) - You have visible signs of excess male hormones, such as unwanted hair growth (hirsutism) or acne - You have irr...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00222066 — University Hospital, Tours

NCT00222066 · University Hospital, Tours
Completed Not Applicable Est. completion 1 January 2007
🇫🇷 FR

Who might be able to join this trial: - You are pregnant with a single baby (not twins or more) and your pregnancy has been going smoothly - Your unborn baby has been identified as a girl - Your baby girl has been found to have a simple flu...

Trial: NCT00972205 — National Cancer Institute (NCI)

NCT00972205 · National Cancer Institute (NCI)
Completed Not Applicable Est. completion 1 June 2009
🇺🇸 US

**Who might be able to join this trial:** - You must be older than 18 years of age. - You must have a confirmed diagnosis (through tissue or cell testing done at the NCI Laboratory of Pathology) of a recurrent, returning, or advanced/sprea...

Trial: NCT01256944 — Taipei Medical University WanFang Hospital

NCT01256944 · Taipei Medical University WanFang Hospital
Completed Not Applicable Est. completion 1 June 2013
🇹🇼 TW

Who might be able to join this trial: - Women who are of reproductive age (able to have children) - Women who have been diagnosed with Polycystic Ovary Syndrome (PCOS), as well as women who have not been diagnosed with PCOS Who may not be...

Trial: NCT04817449 — University of Exeter

NCT04817449 · University of Exeter
Completed Not Applicable Est. completion 1 October 2023
🇬🇧 GB

Who might be able to join this trial: - You are female - You have symptoms that may suggest ovarian cancer - You are currently receiving treatment for ovarian cancer Who may not be able to join: - You are under 18 years of age - You are un...

Trial: NCT01478685 — Celgene

NCT01478685 · Celgene
Completed Phase 1 Est. completion 17 November 2015
🇫🇷 FR 🇳🇱 NL 🇪🇸 ES 🇺🇸 US

**Who might be able to join this trial:** - You are a man or woman aged 18 or older - You are willing and able to understand and sign a consent form before any study procedures begin - You are able to attend all required study visits and f...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05815862 — Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NCT05815862 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Completed Phase 2 Est. completion 20 August 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with advanced lung cancer or ovarian cancer, confirmed by a lab test of tissue or cell samples - You are between 18 and 75 years old at the time of signing the consent for...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01081639 — Merck KGaA, Darmstadt, Germany

NCT01081639 · Merck KGaA, Darmstadt, Germany
Completed Phase 3 Est. completion 1 September 2004

**Who might be able to join this trial:** - You are a woman who has not yet gone through menopause and are between 18 and 39 years old - You are receiving a man-made hormone called FSH as part of IVF or ICSI fertility treatment - You are ab...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03359850 — Tesaro, Inc.

NCT03359850 · Tesaro, Inc.
Completed Phase 1 Est. completion 16 September 2019
🇺🇸 US

Who might be able to join this trial: - You are 18 years of age or older. - You have been diagnosed with an advanced solid tumour (a type of cancer) that has not responded to standard treatments, is unlikely to benefit from standard treatme...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01466049 — Fujirebio Diagnostics, Inc.

NCT01466049 · Fujirebio Diagnostics, Inc.
Completed Not Applicable Est. completion 1 March 2014
🇺🇸 US

Who might be able to join this trial: - You are female and 18 years of age or older - You have a growth or lump near your ovaries or fallopian tubes that has been confirmed by a scan or imaging test - You are already scheduled to have surge...

Trial: NCT00928642 — Henry M. Jackson Foundation for the Advancement of Military Medicine

NCT00928642 · Henry M. Jackson Foundation for the Advancement of...
Completed Phase 2 Est. completion 1 November 2010
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with ovarian cancer or primary peritoneal cancer, confirmed by a tissue sample (biopsy), including types such as mucinous, serous, endometri...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03471572 — AstraZeneca

NCT03471572 · AstraZeneca
Completed Not Applicable Est. completion 21 December 2018
🇮🇳 IN

Who might be able to join this trial: - You are willing and able to sign a written consent form to take part in the study - You are a woman aged 18 or older - You have been diagnosed with ovarian cancer, primary peritoneal cancer, or fallop...

Trial: NCT00791778 — Bayer

NCT00791778 · Bayer
Completed Phase 2 Est. completion 1 July 2011
🇧🇪 BE 🇨🇦 CA 🇫🇮 FI 🇫🇷 FR 🇩🇪 DE

**Who might be able to join this trial:** - You have been diagnosed with advanced ovarian cancer (stage III or IV) or a related cancer called primary peritoneal cancer, confirmed by laboratory testing of tissue samples. - After surgery to r...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01226316 — AstraZeneca

NCT01226316 · AstraZeneca
Completed Phase 1 Est. completion 26 April 2019
🇨🇦 CA 🇩🇰 DK 🇫🇷 FR 🇮🇹 IT 🇯🇵 JP

**Who might be able to join this trial:** - You must be at least 18 years old. - For Parts A and B: You have a solid tumour cancer (not lymphoma) that has stopped responding to standard treatments, or there are no standard treatments avail...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03823833 — University Hospital, Lille

NCT03823833 · University Hospital, Lille
Completed Not Applicable Est. completion 4 April 2025
🇫🇷 FR

Who might be able to join this trial: - Women who have a non-cancerous ovarian cyst that is likely to come back, such as an endometrioma (chocolate cyst), dermoid cyst, or mucinous cyst - Women who have had previous ovarian surgery and/or h...

Trial: NCT00261027 — Ottawa Hospital Research Institute

NCT00261027 · Ottawa Hospital Research Institute
Completed Phase 2 Est. completion 1 July 2007
🇨🇦 CA

**Who might be able to join this trial:** - You are 18 years old or older and have been diagnosed with metastatic (stage II–IV) ovarian cancer that has been confirmed by laboratory testing of tissue or fluid samples. - You have had your ova...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00531570 — NYU Langone Health

NCT00531570 · NYU Langone Health
Completed Not Applicable
🇺🇸 US

Who might be able to join this trial: - You must be a woman over the age of 21 - You must have a complex growth or cyst near your ovaries or fallopian tubes that has been identified by an ultrasound scan and needs to be treated with surgery...

Trial: NCT01319162 — Göteborg University

NCT01319162 · Göteborg University
Completed Not Applicable Est. completion 11 January 2017
🇸🇪 SE

**Who might be able to join this trial:** - You have been diagnosed with, or show signs of, Polycystic Ovary Syndrome (PCOS) — this means having at least one of the following: higher-than-normal male hormone levels (shown by symptoms or a b...

Trial: NCT05982236 — University Hospital, Lille

NCT05982236 · University Hospital, Lille
Completed Not Applicable Est. completion 26 December 2023
🇫🇷 FR

**Who might be able to join this trial:** - You are female - You are 18 years of age or older - You are able to read and write in French - You have previously been diagnosed with Polycystic Ovary Syndrome (PCOS) based on having at least 2 o...

Trial: NCT05113030 — Postgraduate Institute of Dental Sciences Rohtak

NCT05113030 · Postgraduate Institute of Dental Sciences Rohtak
Completed Not Applicable Est. completion 15 June 2022
🇮🇳 IN

"Who might be able to join this trial: - You must be female and have recently been diagnosed with Polycystic Ovary Syndrome (PCOS) using a specific set of medical guidelines called the Rotterdam criteria. - You must be between 11 and 19 yea...

Trial: NCT05769426 — The University of Texas Medical Branch, Galveston

NCT05769426 · The University of Texas Medical Branch, Galveston
Completed Not Applicable Est. completion 31 August 2024
🇺🇸 US

**Who might be able to join this trial:** - People of any race or ethnicity are welcome - Women between 18 and 40 years old who are of childbearing age (for the PCOS pre-menopause group only) - Women aged 50 or older who have gone through m...

Trial: NCT00073944 — BioCryst Pharmaceuticals

NCT00073944 · BioCryst Pharmaceuticals
Completed Phase 1 Est. completion 1 January 2005
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a blood cancer (such as leukemia or lymphoma) that has stopped responding to at least one previous treatment attempt. - OR you have been diagnosed with one of the fol...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00158145 — National Institute on Drug Abuse (NIDA)

NCT00158145 · National Institute on Drug Abuse (NIDA)
Completed Not Applicable Est. completion 1 April 2007
🇺🇸 US

Who might be able to join this trial: - You are currently a smoker - You plan to keep smoking for the 12 months after joining the trial Who may not be able to join: - You have a physical or mental health condition that is currently unstabl...

Trial: NCT05132868 — Stanford University

NCT05132868 · Stanford University
Completed Not Applicable Est. completion 28 June 2023
🇺🇸 US

**Who might be able to join this trial:** - You prefer to receive medical information in Spanish AND you or a family member has had cancer (any type). - You prefer to receive medical information in English AND you or a family member has ha...

Trial: NCT00002568 — Gynecologic Oncology Group

NCT00002568 · Gynecologic Oncology Group
Completed Phase 3 Est. completion 1 December 2004
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with primary ovarian cancer that has been confirmed by a tissue sample (biopsy) - Your cancer is Stage III, meaning more than 1 cm of cancer remained in the abdomen after...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02900625 — Centre Hospitalier Universitaire de Besancon

NCT02900625 · Centre Hospitalier Universitaire de Besancon
Completed Not Applicable Est. completion 1 May 2020
🇫🇷 FR

**Who might be able to join this trial:** - You have had your ovarian tissue frozen and stored (cryopreserved) at some point in the past - You have been diagnosed with premature ovarian insufficiency (where the ovaries stop working properly...

Trial: NCT01600833 — Taipei Medical University WanFang Hospital

NCT01600833 · Taipei Medical University WanFang Hospital
Completed Not Applicable Est. completion 1 March 2013
🇹🇼 TW

Who might be able to join this trial: - You are female and had a full assessment for polycystic ovary syndrome (PCOS) at the Reproductive Endocrinology Clinic at Wan Fang Medical Center, Taipei Medical University, between January 1, 2008 an...

Trial: NCT01382576 — Gulhane School of Medicine

NCT01382576 · Gulhane School of Medicine
Completed Not Applicable Est. completion 1 December 2010
Turkey (Türkiye)

**Who might be able to join this trial:** - You have a normal physical exam result, except for excessive hair growth (hirsutism) - You are not currently taking any medications to lower cholesterol, control blood sugar, manage blood pressure...

Trial: NCT06970821 — Bagcilar Training and Research Hospital

NCT06970821 · Bagcilar Training and Research Hospital
Completed Not Applicable Est. completion 15 May 2025
Turkey (Türkiye)

**Who might be able to join this trial:** - You are a female teenager between the ages of 13 and 19 - You got your first period at least 2 years before joining the study - *(For the PCOS group)* You have been diagnosed with polycystic ovary...

Trial: NCT01689714 — Endocyte

NCT01689714 · Endocyte
Completed Phase 2

**Who might be able to join this trial:** - You must be 18 years of age or older. - You must have a known or strongly suspected diagnosis of ovarian cancer, or returning endometrial cancer, with at least one detectable growth larger than 1....

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01719926 — UMC Utrecht

NCT01719926 · UMC Utrecht
Completed Phase 1 Est. completion 30 August 2017
🇳🇱 NL 🇨🇭 CH

**Who might be able to join this trial:** - You have been diagnosed with a cancer that has been confirmed by a tissue sample (biopsy), and you are receiving certain chemotherapy treatments containing cisplatin (with gemcitabine or 5FU/cape...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02093598 — MedSIR

NCT02093598 · MedSIR
Completed Phase 2 Est. completion 1 March 2014
🇪🇸 ES

**Who might be able to join this trial:** - You have been diagnosed with endometrial (uterine) cancer, confirmed through a tissue sample test - Your cancer is at an early stage (Stage I or Stage II, any grade) and surgery is planned as the...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00228358 — University of Washington

NCT00228358 · University of Washington
Completed Phase 1 Est. completion 1 May 2011
🇺🇸 US

**Who might be able to join this trial:** - You have breast cancer, ovarian cancer, or non-small cell lung cancer that has spread to other parts of the body, is getting worse, and cannot be cured with standard treatments (including the dru...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00946140 — Memorial Sloan Kettering Cancer Center

NCT00946140 · Memorial Sloan Kettering Cancer Center
Completed Not Applicable Est. completion 1 October 2013
🇺🇸 US

**Who might be able to join this trial:** - You have at least one tumor that can be measured (larger than 1 cm) on a CT or MRI scan, and that tumor has not already been treated with surgery or radiation therapy. - You are scheduled to star...

Trial: NCT00053365 — National Cancer Institute (NCI)

NCT00053365 · National Cancer Institute (NCI)
Completed Phase 2 Est. completion 1 July 2010
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with ovarian cancer or primary peritoneal cancer (a related cancer starting in the lining of the abdomen), confirmed by a laboratory test on a tissue sample - Your cancer...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00757185 — Yale University

NCT00757185 · Yale University
Completed Early Phase 1 Est. completion 1 April 2012
🇺🇸 US

Who might be able to join this trial: - Women between the ages of 18 and 35 who are obese, either with or without a condition called PCOS (Polycystic Ovary Syndrome, a hormonal condition affecting the ovaries) Who may not be able to join:...

Early Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00189566 — ARCAGY/ GINECO GROUP

NCT00189566 · ARCAGY/ GINECO GROUP
Completed Phase 2
🇫🇷 FR

**Who might be able to join this trial:** - You are over 18 years old - You have been diagnosed with cancer of the ovary, fallopian tube, or peritoneum, confirmed by a laboratory test on tissue - Your cancer has spread to the lining of the...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03131102 — Aarne Feldheiser

NCT03131102 · Aarne Feldheiser
Completed Not Applicable Est. completion 9 October 2018
🇩🇪 DE

**Who might be able to join this trial:** - You have been diagnosed with epithelial ovarian cancer (a type of ovarian cancer) and are scheduled to have surgery to remove as much of the cancer as possible at the Gynecology Department at Camp...

Trial: NCT02151370 — Hoffmann-La Roche

NCT02151370 · Hoffmann-La Roche
Completed Not Applicable Est. completion 1 September 2013
El Salvador

Who might be able to join this trial: - You must be a woman aged 18 or older - You must have been diagnosed with advanced epithelial ovarian cancer, confirmed through a tissue sample (biopsy) - You must have had a build-up of fluid in the a...